Many parents unaware of 2014-2015 Disneyland measles outbreak

Article Type
Changed
Display Headline
Many parents unaware of 2014-2015 Disneyland measles outbreak

A significant number of parents were unaware of the 2014-2015 United States measles outbreak despite significant media attention, according to Michael Cacciatore, Ph.D., of the department of advertising and public relations at Grady College, University of Georgia, Athens, and his associates.

In a pair of national surveys of parents with children less than 5 years old, 53% (n=523) reported awareness of the measles outbreak centered at Disneyland in California and 33% (n=332) had no knowledge. The remaining 14% responded “don’t know” and were excluded from further study. Parents who were aware of the outbreak were more likely to be white, older, and slightly better educated.

CDC/ Cynthia S. Goldsmith; William Bellini, Ph.D.

Parents who were unaware of the outbreak had fairly high levels of vaccine confidence, but also had the highest levels of concern regarding vaccination, and were most likely to skip recommended vaccinations. Parents with low awareness had fairly high confidence levels, low levels of concern, and were most likely to have their children vaccinated. Parents with high levels of awareness had the highest level of confidence, but also had fairly significant levels of concern; “this suggests those paying most attention to vaccine-preventable diseases fall into both the vaccine proponent and vaccine skeptic camps,” Dr. Cacciatore and his associates found.

“Highly visible or publicized outbreaks can positively affect awareness, intentions, and support for public health measures, but those responsible for informing and guiding public or parental actions need to recognize that their efforts must continue to go beyond traditional news media. In today’s crowded communication and media landscapes, individuals have much flexibility and great freedom in the types of information they view; thus, even major public health events are not guaranteed to reach all audiences, including those most in need of the information,” the investigators concluded.

Find the full study in Health Affairs (doi: 0.1377/hlthaff.2015.1093).

lfranki@frontlinemedcom.com

References

Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

A significant number of parents were unaware of the 2014-2015 United States measles outbreak despite significant media attention, according to Michael Cacciatore, Ph.D., of the department of advertising and public relations at Grady College, University of Georgia, Athens, and his associates.

In a pair of national surveys of parents with children less than 5 years old, 53% (n=523) reported awareness of the measles outbreak centered at Disneyland in California and 33% (n=332) had no knowledge. The remaining 14% responded “don’t know” and were excluded from further study. Parents who were aware of the outbreak were more likely to be white, older, and slightly better educated.

CDC/ Cynthia S. Goldsmith; William Bellini, Ph.D.

Parents who were unaware of the outbreak had fairly high levels of vaccine confidence, but also had the highest levels of concern regarding vaccination, and were most likely to skip recommended vaccinations. Parents with low awareness had fairly high confidence levels, low levels of concern, and were most likely to have their children vaccinated. Parents with high levels of awareness had the highest level of confidence, but also had fairly significant levels of concern; “this suggests those paying most attention to vaccine-preventable diseases fall into both the vaccine proponent and vaccine skeptic camps,” Dr. Cacciatore and his associates found.

“Highly visible or publicized outbreaks can positively affect awareness, intentions, and support for public health measures, but those responsible for informing and guiding public or parental actions need to recognize that their efforts must continue to go beyond traditional news media. In today’s crowded communication and media landscapes, individuals have much flexibility and great freedom in the types of information they view; thus, even major public health events are not guaranteed to reach all audiences, including those most in need of the information,” the investigators concluded.

Find the full study in Health Affairs (doi: 0.1377/hlthaff.2015.1093).

lfranki@frontlinemedcom.com

A significant number of parents were unaware of the 2014-2015 United States measles outbreak despite significant media attention, according to Michael Cacciatore, Ph.D., of the department of advertising and public relations at Grady College, University of Georgia, Athens, and his associates.

In a pair of national surveys of parents with children less than 5 years old, 53% (n=523) reported awareness of the measles outbreak centered at Disneyland in California and 33% (n=332) had no knowledge. The remaining 14% responded “don’t know” and were excluded from further study. Parents who were aware of the outbreak were more likely to be white, older, and slightly better educated.

CDC/ Cynthia S. Goldsmith; William Bellini, Ph.D.

Parents who were unaware of the outbreak had fairly high levels of vaccine confidence, but also had the highest levels of concern regarding vaccination, and were most likely to skip recommended vaccinations. Parents with low awareness had fairly high confidence levels, low levels of concern, and were most likely to have their children vaccinated. Parents with high levels of awareness had the highest level of confidence, but also had fairly significant levels of concern; “this suggests those paying most attention to vaccine-preventable diseases fall into both the vaccine proponent and vaccine skeptic camps,” Dr. Cacciatore and his associates found.

“Highly visible or publicized outbreaks can positively affect awareness, intentions, and support for public health measures, but those responsible for informing and guiding public or parental actions need to recognize that their efforts must continue to go beyond traditional news media. In today’s crowded communication and media landscapes, individuals have much flexibility and great freedom in the types of information they view; thus, even major public health events are not guaranteed to reach all audiences, including those most in need of the information,” the investigators concluded.

Find the full study in Health Affairs (doi: 0.1377/hlthaff.2015.1093).

lfranki@frontlinemedcom.com

References

References

Publications
Publications
Topics
Article Type
Display Headline
Many parents unaware of 2014-2015 Disneyland measles outbreak
Display Headline
Many parents unaware of 2014-2015 Disneyland measles outbreak
Article Source

FROM HEALTH AFFAIRS

PURLs Copyright

Inside the Article

Early-wheezing Patterns Prefigure Adolescent Respiratory Outcomes and Asthma

Article Type
Changed
Display Headline
Early-wheezing Patterns Prefigure Adolescent Respiratory Outcomes and Asthma

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

References

Author and Disclosure Information

Alice Goodman, Family Practice News Digital Network

Publications
Topics
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Sections
Author and Disclosure Information

Alice Goodman, Family Practice News Digital Network

Author and Disclosure Information

Alice Goodman, Family Practice News Digital Network

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Early-wheezing Patterns Prefigure Adolescent Respiratory Outcomes and Asthma
Display Headline
Early-wheezing Patterns Prefigure Adolescent Respiratory Outcomes and Asthma
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Sections
Article Source

FROM JAMA PEDIATRICS

PURLs Copyright

Inside the Article

Books, text messages increase sun protection behaviors

Engage caregiver and child for sun protection
Article Type
Changed
Display Headline
Books, text messages increase sun protection behaviors

An intervention consisting of text-message reminders, read-along books, and swim shirts achieved significant improvements in sun protection behaviors in children, compared with information about sun protection alone, according to the results of a randomized controlled trial.

The study, published online Feb. 8 in JAMA Pediatrics, enrolled 300 caregiver-child pairs (children aged 2-6 years), randomizing 153 to receive a read-along book emphasizing sun protection behaviors, a swim shirt, and weekly text messages asking about sun protection measures undertaken and 147 to the usual information about sun protection given at a well-child visit.

©Vesna Andjic/iStockphoto.com

After 4 weeks, the intervention group showed significantly higher scores for sunscreen use both on sunny and cloudy days, significantly higher scores relating to wearing a shirt on sunny days, and significantly lower increases in skin melanin indices on the sun-protected upper arm, compared with the control group (JAMA Pediatr. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4373).

“Pediatricians’ seasonal age-specific sun protection recommendations will be more effective if supported by an effective, easily accessible, multicomponent program that can be reinforced at home,” said Byron K. Ho of Northwestern University, Chicago, and his coauthors.

The study was funded by the Pediatric Sun Protection Foundation. No conflicts of interest were declared.

References

Body

The choice by the investigators to educate both the caregiver and the child through the use of an active read-aloud book was a pragmatic one because this process engages both caregivers and their children to recruit each other in reinforcing recommended behaviors.

Supplying rather than simply recommending sun-protective clothing as part of the study encourages adherence by eliminating the obstacle of having families purchase the sun-protective clothing themselves, thus removing associated economic barriers.

D. Albert C. Yan and Dr. Leslie Castelo-Soccio are with the section of dermatology at the Children’s Hospital of Philadelphia and from the departments of pediatrics and dermatology at the University of Pennsylvania. These comments are excerpted from an accompanying editorial (JAMA Pediatr. Feb 8. doi: 10.1001/jamapediatrics.2015.4524). Dr. Yan declared consultancies for Galderma, Johnson & Johnson, Pierre Fabre, and Procter & Gamble. No other conflicts of interest were declared.

Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

Body

The choice by the investigators to educate both the caregiver and the child through the use of an active read-aloud book was a pragmatic one because this process engages both caregivers and their children to recruit each other in reinforcing recommended behaviors.

Supplying rather than simply recommending sun-protective clothing as part of the study encourages adherence by eliminating the obstacle of having families purchase the sun-protective clothing themselves, thus removing associated economic barriers.

D. Albert C. Yan and Dr. Leslie Castelo-Soccio are with the section of dermatology at the Children’s Hospital of Philadelphia and from the departments of pediatrics and dermatology at the University of Pennsylvania. These comments are excerpted from an accompanying editorial (JAMA Pediatr. Feb 8. doi: 10.1001/jamapediatrics.2015.4524). Dr. Yan declared consultancies for Galderma, Johnson & Johnson, Pierre Fabre, and Procter & Gamble. No other conflicts of interest were declared.

Body

The choice by the investigators to educate both the caregiver and the child through the use of an active read-aloud book was a pragmatic one because this process engages both caregivers and their children to recruit each other in reinforcing recommended behaviors.

Supplying rather than simply recommending sun-protective clothing as part of the study encourages adherence by eliminating the obstacle of having families purchase the sun-protective clothing themselves, thus removing associated economic barriers.

D. Albert C. Yan and Dr. Leslie Castelo-Soccio are with the section of dermatology at the Children’s Hospital of Philadelphia and from the departments of pediatrics and dermatology at the University of Pennsylvania. These comments are excerpted from an accompanying editorial (JAMA Pediatr. Feb 8. doi: 10.1001/jamapediatrics.2015.4524). Dr. Yan declared consultancies for Galderma, Johnson & Johnson, Pierre Fabre, and Procter & Gamble. No other conflicts of interest were declared.

Title
Engage caregiver and child for sun protection
Engage caregiver and child for sun protection

An intervention consisting of text-message reminders, read-along books, and swim shirts achieved significant improvements in sun protection behaviors in children, compared with information about sun protection alone, according to the results of a randomized controlled trial.

The study, published online Feb. 8 in JAMA Pediatrics, enrolled 300 caregiver-child pairs (children aged 2-6 years), randomizing 153 to receive a read-along book emphasizing sun protection behaviors, a swim shirt, and weekly text messages asking about sun protection measures undertaken and 147 to the usual information about sun protection given at a well-child visit.

©Vesna Andjic/iStockphoto.com

After 4 weeks, the intervention group showed significantly higher scores for sunscreen use both on sunny and cloudy days, significantly higher scores relating to wearing a shirt on sunny days, and significantly lower increases in skin melanin indices on the sun-protected upper arm, compared with the control group (JAMA Pediatr. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4373).

“Pediatricians’ seasonal age-specific sun protection recommendations will be more effective if supported by an effective, easily accessible, multicomponent program that can be reinforced at home,” said Byron K. Ho of Northwestern University, Chicago, and his coauthors.

The study was funded by the Pediatric Sun Protection Foundation. No conflicts of interest were declared.

An intervention consisting of text-message reminders, read-along books, and swim shirts achieved significant improvements in sun protection behaviors in children, compared with information about sun protection alone, according to the results of a randomized controlled trial.

The study, published online Feb. 8 in JAMA Pediatrics, enrolled 300 caregiver-child pairs (children aged 2-6 years), randomizing 153 to receive a read-along book emphasizing sun protection behaviors, a swim shirt, and weekly text messages asking about sun protection measures undertaken and 147 to the usual information about sun protection given at a well-child visit.

©Vesna Andjic/iStockphoto.com

After 4 weeks, the intervention group showed significantly higher scores for sunscreen use both on sunny and cloudy days, significantly higher scores relating to wearing a shirt on sunny days, and significantly lower increases in skin melanin indices on the sun-protected upper arm, compared with the control group (JAMA Pediatr. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4373).

“Pediatricians’ seasonal age-specific sun protection recommendations will be more effective if supported by an effective, easily accessible, multicomponent program that can be reinforced at home,” said Byron K. Ho of Northwestern University, Chicago, and his coauthors.

The study was funded by the Pediatric Sun Protection Foundation. No conflicts of interest were declared.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Books, text messages increase sun protection behaviors
Display Headline
Books, text messages increase sun protection behaviors
Article Source

FROM JAMA PEDIATRICS

PURLs Copyright

Inside the Article

Vitals

Key clinical point: An intervention of books, text-message reminders, and swim shirts can improve sun protection behaviors in children.

Major finding: A multimodal 4-week intervention aimed at increasing sun protection behavior achieved significant increases in sunscreen use and shirt wearing.

Data source: Randomized controlled study involving 300 caregiver-child pairs.

Disclosures: The study was funded by the Pediatric Sun Protection Foundation. No conflicts of interest were declared.

Early-wheezing patterns prefigure adolescent respiratory outcomes and asthma

Article Type
Changed
Display Headline
Early-wheezing patterns prefigure adolescent respiratory outcomes and asthma

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

References

Click for Credit Link
Author and Disclosure Information

Publications
Topics
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Sections
Click for Credit Link
Click for Credit Link
Author and Disclosure Information

Author and Disclosure Information

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

Wheezing patterns in early childhood can predict pulmonary function and the development of asthma in adolescence in a high-risk population, a study finds.

The study validates four clinically distinct early-life wheezing phenotypes identified by the landmark Tucson Children’s Respiratory Study in a high-risk population:

• Never.

• Transient early – wheezing before age 3 years but not at age 6 years.

• Late onset – wheezing at age 6 years but not before age 3 years.

• Persistent – wheezing before age 3 years and at age 6 years.

tupungato/©Thinkstock

Previously, these phenotypes were shown to be associated with respiratory outcomes in adolescence but not with diagnosed asthma or in genetically predisposed children. The present study extends the associations with these early phenotypes to a high-risk adolescent population, said Meghan B. Azad, Ph.D., of the University of Manitoba, Winnipeg, and her associates.

The study findings were based on findings in 459 children previously enrolled in the Canadian Asthma Primary Prevention Study cohort; this was a prenatally randomized prevention trial in children at high genetic risk for asthma. The distribution of early-wheeze phenotypes was 51% never, 28% transient early, 9% late onset, and 13% persistent (JAMA Pediatrics. 2016 Feb 8. doi: 10.1001/jamapediatrics.2015.4127).

Across all four phenotypes, the authors found a strong gradient of decreasing lung function and increasing asthma risk by age 15 years. Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: the prevalence of asthma was 5% among never, 19% among transient early, 27% among late onset, and 42% among persistent phenotypes.

At age 15, early-wheezing phenotypes were not associated with atopic dermatitis or allergic rhinitis. Atopy before 2 years of age was associated with persistent wheeze, which was in turn associated with a 12-fold increased risk of diagnosed asthma by age 15.

“Our results are consistent with other cohorts” and the study “extends these findings through adolescence in a high-risk cohort and demonstrates that asthma-associated deficits are already present at a young age. Collectively, these data show that early wheezing patterns provide clinically meaningful information and suggest that strategies to reduce early-life wheezing and atopic sensitization could have long-term health benefits,” Dr. Azad and her colleagues concluded.

Proven strategies to prevent wheezing include avoiding dust, pets, and tobacco smoke; encouragement of breastfeeding; and delayed introduction of solid foods.

The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Early-wheezing patterns prefigure adolescent respiratory outcomes and asthma
Display Headline
Early-wheezing patterns prefigure adolescent respiratory outcomes and asthma
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Legacy Keywords
wheezing, adolescent, asthma, respiratory
Click for Credit Status
Active
Sections
Article Source

FROM JAMA PEDIATRICS

PURLs Copyright

Inside the Article

Vitals

Key clinical point: Persistent early-life wheezing was associated with an 12-fold increased risk of diagnosed asthma by age 15 years.

Major finding: Asthma, assessed at 15 years in 320 adolescents, was associated with early-wheeze phenotypes: prevalence of asthma was 5% among never, 19% among early transient, 27% among late onset, and 42% among persistent phenotypes.

Data source: A study of 459 children.

Disclosures: The research was supported by the Canadian Institutes of Health Research. The investigators reported no relevant financial disclosures.

Clinician Telephone Training to Reduce Family Tobacco Use: Analysis of Transcribed Recordings

Article Type
Changed
Display Headline
Clinician Telephone Training to Reduce Family Tobacco Use: Analysis of Transcribed Recordings

From the Massachusetts General Hospital for Children, Boston, MA (Walters, Drehmer, Nabi-Burza, Winickoff), the University of Rochester School of Medicine, Rochester, NY (Ossip), and the American Academy of Pediatrics Julius B. Richmond Center of Excellence, Elk Grove Village, IL (Whitmore, Gorzkowski). Deceased 31 December 2015.

 

Abstract

  • Background: Family tobacco use and exposure are significant threats to the health of children and their families. However, few pediatric clinicians address family tobacco use and exposure in a routine and effective manner. The Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice.
  • Objective: To review the main considerations and questions that clinicians and office staff expressed during telephone training to participate in CEASE.
  • Methods: This study was conducted in pediatric practices in 5 US states. Practices were recruited by the American Academy of Pediatrics (10 intervention, 10 control). Ten training calls were recorded and transcribed. The data was then coded inductively based on themes found in the transcripts.
  • Results: The data revealed that clinicians and staff were concerned about prescribing, dosing, and insurance coverage of nicotine replacement therapy; motivation for and methods to help families become tobacco-free; and the impact of the intervention on practice operations.
  • Conclusion: While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco-free, they expressed concerns that could threaten implementation of family tobacco control strategies.

 

 

The devastating health consequences of smoking and exposure to tobacco smoke have been well demonstrated. As declared in the 2006 Surgeon General’s Report, there is no safe level of exposure to tobacco [1]. Children are especially at risk for exposure to toxins and toxicants in tobacco smoke [1,2]. Exposure to tobacco smoke is associated with higher levels of asthma, increased risk of sudden infant death syndrome, increased rates of upper respiratory infections, and behavioral issues [3–5]. Recent research shows that over 70% of children in the United States have some level of exposure to tobacco smoke [6]; parents and other family members are commonly the cause of this exposure, especially in young children. Children and parents benefit when parents stop smoking; parent life expectancy increases by an average of 7 years [7], the risk of tobacco-related poor pregnancy outcomes is reduced, and future children are spared from exposure to tobacco smoke [8].

There is a growing movement to address tobacco use and exposure in the pediatric office setting; the 2015 American Academy of Pediatrics tobacco policy statement Clinical Practice Policy to Protect Children From Tobacco, Nicotine, and Tobacco Smoke recommends that pediatricians ask about children’s exposure to tobacco and address parental tobacco use by implementing office-wide systems to deliver advice, counseling, referral to cessation resources, and smoking cessation medication to smokers [9].

Despite significant risks of tobacco smoke exposure to children, we found in a previous paper that only 3.5% of parents in control practices received any tobacco control assistance [10]. Through a systematic and ongoing line of research, the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice. The CEASE intervention has been successfully shown to train and equip pediatric officesfrom a distance to address family tobacco use within existing office systems [10–14]. An enhanced CEASE intervention is undergoing testing in pediatric practices in 5 US states.

The CEASE intervention works with pediatric primary care offices on strategies to promote routine and effective family-centered tobacco control by addressing parental smoking and establishing smoke-free home and car rules. Based on national guidelines and extensive data obtained in previous pilot testing [12,14–16], elements of the CEASE intervention have been designed to be adapted to individual practices’ staffing, resources, and physical configuration. The main elements of the intervention are identifying tobacco users and children exposed to tobacco smoke through the use of a paper or an electronic tablet screening tool, assisting smokers in setting a quit date, establishing rules for smoke-free homes and cars, prescribing nicotine replacement therapy (NRT) to help smokers cut down or quit [17,18], referring smokers to tobacco quitlines and/or the SmokeFreeTXT program [19–25], and following up with tobacco users. Clinicians and staff are trained in the adoption, implementation, and maintenance of family-centered tobacco control strategies with the goal of embedding the elements of CEASE intervention into routine practice beyond the training and/or research study periods. The CEASE training was designed to meet the needs of pediatric offices, be time- and cost-effective, and be implemented through distance learning strategies to save both trainer and pediatric office staff resources. The training approach consists of a number of evidence-based strategies. As depicted in the Table, the training involves multiple modalities, including videos, reference materials, online computer education modules, and telephone training calls.

One of the more innovative aspects of CEASE has been the use of training calls. In studies of CEASE, the peer-to-peer call was conducted by the principal investigator with the project leader at the practice using a train-the-trainer model. After the project leader was trained through the peer-to-peer call, the project leader then led the whole office training call, with the support of CEASE staff by phone. The training calls worked in conjunction with the other aspects of the training, as shown in the Table. The training calls for the practices provided a valuable research opportunity. We examined the concerns and issues that clinicians and office staff had about implementing an office-wide tobacco control program through a qualitative analysis of the call transcripts. This paper outlines the main considerations and questions that clinicians and office staff expressed during the training calls. Understanding the points of view of clinicians and staff will help researchers and clinical educators strengthen the design of tobacco control interventions.

Methods

Study Aims

The data for this paper were collected as part of a larger mixed-methods controlled trial. The overarching aims of the trial were to study implementation and sustainability of tobacco-control services delivered at the clinic level, to facilitate behavior change among parents and evaluate cost-per-quit among parents who smoke, and to study systems changes and the processes that affect them at the practice level. The study was conducted in 5 intervention and 5 control pediatric primary care practices in 5 states; this paper reports on data collected in intervention practices and focuses on understanding the systems changes and processes that are instituted when implementing a tobacco control program at the clinician and practice level.

Practice Recruitment and Eligibility

Practices were recruited through the American Academy of Pediatrics using direct emails, newsletter/listserv articles, phone calls to members, and in-person recruitment at national meetings. Eligible practices were located in a non–hospital-based setting, had an average patient flow of at least 50 patients per day, used an electronic medical record (EMR) system, and were matched in each state based on practice size and smoking rate. Interested practices also had to be willing to host a research assistant to collect exit interview data from parents. Practices were excluded if they took part in previous CEASE studies or were actively enrolling participants into other tobacco control research studies. Based on these criteria, 18 eligible practices from Indiana, North Carolina, Ohio, Tennessee, Michigan, and Virginia agreed to participate in the study. Of the 6 states, one state was chosen as a replacement state. Five practices from the remaining states were assigned to the intervention group, 5 to the control group, and 5 were assigned to the replacement group in case an intervention or control practice in their state withdrew from the study. Each intervention practice participated in a peer-to-peer training call and a whole office training call. Data analyzed in this paper was collected from all 10 intervention practice training calls.

Training Calls Data Collection

The peer-to-peer and whole office training calls were recorded and transcribed. Permission to record the calls was requested by the trainer (the principal investigator of the study) and given verbally by each person being trained. The training call recordings were then transcribed verbatim by a commercial service; the transcriptions were spot-checked for accuracy.

The transcripts were first read closely by the first author (BHW), then coded inductively into relevant themes that emerged from the calls. The inductive coding was guided by the questions and concerns that the clinicians raised during the training, as well as the ways in which the trainer addressed these concerns and tailored the training to the needs and interests of the pediatric clinicians [26]. The coding was reviewed and confirmed by the other study team members.

 

 

After the data were coded into themes, the coded data were analyzed by the first author using qualitative description. Qualitative description is a method of analyzing coded qualitative data by looking at the words and meanings expressed by respondents [27]. Through this method of analysis, we were able to understand what concerns the clinicians and staff voiced about aspects of the CEASE intervention.

Ethics

The study was approved institutional review boards at Massachusetts General Hospital, the AAP, and the health care practices that required local IRB approval. The quotes used in this paper have been anonymized and cleaned to remove any identifying information, such as location and names.

Peer-to-Peer Training Calls

The peer-to-peer training calls were conducted after training and study materials arrived. The project leader (a pediatrician in the practice who was interested in spearheading the CEASE intervention) was asked to watch the training video. Using an evidence-based, previously developed call script [28], the principal investigator trained the project leader in key aspects of addressing family tobacco use and exposure, such as using an electronic tablet screener survey to identify family members who smoke, exploring techniques for prescribing or recommending NRT, and identifying ways to connect family members to free tobacco cessation counseling and support services. On occasion, other staff from the pediatric office (eg, a nurse or office manager) joined the call.

The principal investigator presented information, clarified points in the video, explained the materials, and asked questions and elicited relevant experiences from the project leader. In addition to teaching the project leader about the tobacco control strategies used in CEASE, the peer-to-peer calls prepared the project leader to train the rest of their own practice clinicians and staff in the CEASE intervention.

Whole Office Training Calls

Each practice’s local project leader led the whole office training calls, but CEASE study staff were on the call to introduce themselves to office staff, answer any questions that staff may have raised that the project leader could not answer, give information about data collection, and to generally support the implementation of the CEASE intervention and research program. During this call, the project leader watched the video with the group and tailored the training for his or her practice, focusing on issues of relevance for patients and staff.

Training Calls as Research Data

As many practices struggle with research burden [29], finding innovative and unobtrusive methods of collecting data is especially useful for research teams and participating practices. During both calls, clinicians and staff were asked open-ended questions to learn about their concerns regarding intervention implementation, share their own experiences with tobacco and tobacco control, and explore practice-specific methods to address family smoking. CEASE staff used this opportunity to help practices tailor the intervention to the local setting, such as by offering quitline enrollment sheets in another language. Clinician and staff answers to open-ended questions provided qualitative data for this manuscript.

Results and Discussion

The research team used training call data to explore clinician and staff concerns and desires related to family-centered tobacco control. The most common themes were: (1) prescribing, dosing, and insurance coverage of NRT, (2) motivation for and methods to help families become tobacco-free, and (3) the impact of the CEASE intervention on the day-to-day operations of the practice.

Nicotine Replacement Therapy

Prescribing or recommending NRT is one of the best ways to help families become tobacco-free and is a crucial component of the CEASE intervention [30–32]. Through the telephone trainings, clinicians and staff were trained to prescribe NRT using pre-printed prescription sheets, presented information about the effectiveness of NRT for smoking cessation, and referred to an information sheet on NRT to answer other questions as needed.

During the calls, it became clear that the pediatric clinicians were interested in prescribing NRT to help smokers quit, but lacked the skills and knowledge to do so:

I’m writing all this down [about NRT], because I don’t know any of this. (IN peer-to-peer)

Is 4 mg the strongest the gum comes in? (NC whole office)

This lack of knowledge may be a barrier to prescribing NRT in the pediatric setting. A national survey revealed that while smoking parents would accept prescriptions for NRT from their child’s doctor, very few received a prescription [33]. The calls provided an opportunity to have clinicians’ questions about NRT be answered by a pediatric tobacco control expert.

Clinicians were interested in helping parents stop smoking with medication, but were worried about access to medication; one of the most common questions voiced was not about how or why to prescribe NRT but how to help low-income parents get NRT for free or low-cost.

Some people—they don’t have insurance, so, how much it costs, they need to know that. (TN peer-to-peer)

I just know I’ve got a bunch ... Obamacare doesn’t work down here, so—I’ve still got families who don’t have any insurance, and you’re like, “Oh, I was hoping you could get something,” and they’re like, “Well, we can’t.” I have a fair number of kids who—are on some type of insurance, but the parents don’t have any coverage for NRT. (VA peer-to-peer)

While NRT is covered under the Affordable Care Act, many states have not expanded their Medicaid coverage [34]; this leaves many low-income families without access to health insurance or to free or low-cost NRT. While NRT remains one of the best and most common smoking cessation tools [35] there was no way to reassure practices that parents would be able to obtain the prescribed NRT without guaranteed coverage. In a previous study, the cost of NRT was seen by smokers as a barrier to using NRT to quit smoking [32]. Clinicians’ concerns about the cost of NRT reveal an understanding of the needs and issues relevant to their patient population.

Motivation for and Methods to Help Families Become Tobacco-Free

Clinicians and office staff were motivated to help families become tobacco-free and were interested in various ways to do so. The motivation and interest were personal, clinical, and organizational, relating to the ways in which care in the pediatric office could be altered to address tobacco in a more systematic way.

 

 

Motivation

The interest in smoking cessation stems from the desire to protect children from the harmful effects tobacco smoke and to prevent children themselves from taking up smoking:

We’d always talked about the smoking, and the parents finally quit. Probably not like I helped them—I just had been harping on them—but by that point the boy was smoking. When he was little he was like, “Oh, that’s nasty. I can’t believe my parents smoke.” Then by the time he was 14-15 and the parents actually did manage to quit, he was smoking, and I was like, “Ugh, really?” (VA peer-to-peer)

I totally understand the dire need for this project, in both the tobacco in the households, as well as the teenagers smoking. I heard one stat[istic], that one of our high schools had 80% of children using tobacco products… And that’s on my watch… I understand and I share the same passion that you do, for personal reasons, as well as reasons to help the whole community. (NC peer-to-peer)

Pediatricians saw themselves as responsible for protecting children’s health through reducing their tobacco smoke exposure, for working to prevent teen smoking, and for the overall health of their communities. Helping prevent childhood exposure to tobacco smoke and teen smoking initiation are crucial tasks for pediatricians; the 2015 AAP tobacco policy statement strongly recommends that pediatric offices include tobacco use prevention messages when talking to children and teens to help prevent smoking initiation, as well as helping families establish smoking bans for homes and cars [36]. By participating in the CEASE telephone trainings, clinicians and office staff were learning skills and tools to help them act on their motivation to protect families from the harms of tobacco.

Strategies

Pediatricians and office staff were interested in learning specific strategies and tools to help parents stop smoking. Practices wanted to know how and when to set a quit date with families, how to use services to help families become smoke-free, and how to tailor assistance to specific populations.

Yeah, we’re wondering about other languages, because we do have a large Hispanic patient population and a sizable group of folks that come from Saudi Arabia, and I know that some of them do smoke. (TN peer-to-peer)

Set[ting] a quit date for the patient —so how long we want to set the date? 6 months, 3 months, 1 year, 2 years, what? (TN peer-to-peer)

If you have a mom who lives with grandma and grandpa, the mom may not smoke but grandma and grandpa smoke, but they still live in that home… But anyone who comes in, we’re going to help. Does that sound right? (VA peer-to-peer)

By participating in the study, the clinicians and office staff were actively seeking to improve their knowledge of tobacco-related issues; past research has shown that pediatric residents saw lack of training in tobacco control as a key reason for inconsistent tobacco control outreach and intervention [37]. The training calls were an opportunity to gain information more specifically related to the pediatric practice’s population and office setting, building upon the other CEASE training materials. The training calls were also a chance for the CEASE research team to adapt strategies and tools to the practices, for example by providing materials that met the practices’ needs.

Impact of Intervention on Day-To-Day Operations

The training calls revealed that integrating CEASE into office workflows was a major concern. Integrating preventive services into routine office practice is a frequent concern of primary care providers [38–41]. These concerns about office flow reflect worries about financing [42] and benchmarking [43–45].

I think they’re going to have some of the same questions [that I initially had] in terms of how this might work with workflow. But as we’ve talked through all of this, I think we can make it work, and make it just sort of incorporated as part of our everyday questions that we ask. And it shouldn’t really slow things down. And I think that’ll be the main thing the providers would be focusing on is, how’s this going to impact me and all the other things I have to do in the course of a visit? This [phone call] answers a lot of questions I had in terms of that. (IN peer-to-peer)

As wait time was a performance measure for many of the practices, the clinicians and staff were hesitant to add any activities to check-in that might increase wait time.

I know, so especially, we’re trying to do a care team right now... don’t want them to spend too much time in the waiting room. (OH whole office)

During the calls, clinicians and office staff were asked to reflect on their practices and discuss ways that their practice would implement the CEASE intervention. This moment of reflection is a benefit of research participation, as it allows practices to improve the care they provide [46]. The calls allowed for on-the-spot tailoring of the intervention to meet the specific needs of the practice, an opportunity for the research staff and practice to work together to make the intervention fit their particular office situation and flow. Data collected from the training calls were also reviewed during the CEASE implementation process to support practices with specific concerns.

Strengths and Limitations

As these data were collected during training calls and subject to social desirability bias, the concerns raised may not be an exhaustive list of all concerns that clinicians and office staff had. However, the concerns that were raised by clinicians became a natural and essential part of the training process. As the practices’ initial concerns were identified early in the study, it was possible to address these concerns throughout the early implementation phases of CEASE. Transcribing calls and analyzing training call data as quickly as possible during the training phases of an intervention could prove beneficial for strengthening the implementation.

Dedicating the extra time and effort to record the training calls as a source of data formalized and strengthened the implementation process. By recording training calls, the study team was able to document the practices’ concerns and share them among the research team, including those who were not on training calls. This effort was a significant source of quality improvement data for the research team and helped ensure that we were responsive to the articulated needs of clinicians and practices.

 

 

Conclusion

The training call data revealed both the concerns as well as the interests of child health care clinicians in regard to addressing family tobacco use. While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco free, they expressed concerns that could threaten full implementation of family tobacco control strategies. These concerns and interests related to the coverage and affordability of NRT, integrating tobacco control strategies into the practice flow, and learning strategies to address family-wide tobacco use, such as helping grandparents quit smoking or addressing tobacco use with those who were not native English speakers. The concerns and interests of clinicians and office staff revealed that they were genuinely interested in learning ways to tailor strategies to address tobacco use for their practices and patient populations. By recording the training calls, the study team was better able to help them tailor the intervention to their practice, both during the calls and during subsequent implementation by providing new materials and additional information on subjects of concern to the practice. Carefully documenting training calls with health care practices are an ideal opportunity to collect information on issues that may impact full implementation of future interventions.

Corresponding author: Jonathan P. Winickoff, jwinickoff@mgh.harvard.edu

References

1. U.S. Department of Health and Human Services. The health consequences of involuntary tobacco smoke: a report of the Surgeon General. 2006.

2. Rauh VA, Whyatt RM, Garfinkel R, et al. Developmental effects of exposure to environmental tobacco smoke and material hardship among inner-city children. Neurotoxicol Teratol 2004;26:373–85.

3. Polanska K, Hanke W, Ronchetti R, et al. Environmental tobacco smoke exposure and children’s health. Acta Paediatr Suppl 2006;95:86–92.

4. American Academy of Pediatrics, Committee on Substance Abuse. Tobacco’s toll: implications for the pediatrician. Pediatrics 2001;107:794–8.

5. U.S. Department of Health and Human Services. Children and secondhand smoke exposure. Excerpts from the health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon GeneralAtlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health2007.

6. Wilson KM, Klein JD, Blumkin AK, et al. Tobacco-smoke exposure in children who live in multiunit housing. Pediatrics 2011;127:85–92.

7. Taylor SM, Ross NA, Cummings KM, et al. Community intervention trial for smoking cessation (COMMIT): changes in community attitudes toward cigarette smoking. Health Educ Res 1998;13:109-22.

8. Winickoff JP, Healey EA, Regan S, et al. Using the postpartum hospital stay to address mothers’ and fathers’ smoking: the NEWS study. Pediatrics 2010;125:518–25.

9. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Clinical practice policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:1008–17.

10. Winickoff JP, Nabi-Burza E, Chang Y, et al. Implementation of a parental tobacco control intervention in pediatric practice. Pediatrics 2013;132:109–17.

11. Ossip DJ, Chang Y, Nabi-Burza E, et al. Strict smoke-free home policies among smoking parents in pediatric settings. Acad Pediatr 2013;13:517–23.

12. Winickoff JP, Park ER, Hipple BJ, et al. Clinical effort against secondhand smoke exposure: development of framework and intervention. Pediatrics 2008;122:e363–e75.

13. Nabi-Burza E, Winickoff JP, Finch S, Regan S. Triple tobacco screen: opportunity to help families become smokefree. Am J Prev Med 2013;45:728–31.

14. Winickoff JP. Pediatrician-led program increases provision of smoking cessation support, boosts quit rates among parents. Innovations in Medicine 2011. Accessed 24 Nov 2015 at https://innovations.ahrq.gov/profiles/pediatrician-led-program-increases-provision-smoking-cessation-support-boosts-quit-rates.

15. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.

16. Winickoff JP, Nabi-Burza E, Chang Y, et al. Sustainability of a parental tobacco control intervention in pediatric practice. Pediatrics 2014;134:933-41.

17. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.

18. Aveyard P, Wang D, Connock M, et al. Assessing the outcomes of prolonged cessation-induction and aid-to-cessation trials: floating prolonged abstinence. Nicotine Tob Res 2009;11:475–80.

19. Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011;36:764–8.

20.Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998;339:673–9.

21. Abroms LC, Ahuja M, Kodl Y, et al. Text2Quit: Results from a pilot test of a personalized, interactive mobile health smoking cessation program. J Health Commun 2012;17 Suppl 1:44-53.

22. Curry SJ, Ludman EJ, Graham E, et al. Pediatric-based smoking cessation intervention for low-income women: a randomized trial. Arch Pediatr Adolesc Med 2003;157:295–302.

23. Orleans CT, Schoenbach VJ, Wagner EH. Self-help quit smoking interventions: effects of self-help materials, social support materials, social support instructions and telephone counseling. J Consult Clin Psychol 1991;59:439–48.

24. An LC, Zhu SH, Nelson DB, et al. Benefits of telephone care over primary care for smoking cessation: a randomized trial. Arch Intern Med 2006;166:536–42.

25. Warner DO, Klesges RC, Dale LC, et al. Clinician-delivered intervention to facilitate tobacco quitline use by surgical patients. Anesthesiology 2011;114:847–55.

26. Creswell, JW. Qualitative inquiry and research design: choosing among five approaches. 2nd ed. Thousand Oaks, CA: Sage; 2007.

27. Sandelowski M. Focus on research methods: whatever happened to qualitative description. Res Nurs Health 2000;23:334–40.

28. Winickoff JP, Hipple B, Drehmer J, et al. The clinical effort against secondhand smoke exposure (CEASE) intervention: A decade of lessons learned. J Clin Outcomes Manag 2012;19:414–9.

29. Clark T, Sinclair R. The costs and benefits of acting as a research site. Evid Policy A J Res Debate Pract 2008;4:105–19.

30. Zhu S, Melcer T, Sun J. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305–11.

31. Gilpin EA, Messer K, Pierce JP. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res 2006;8:661–9.

32. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med 2005;28:119–22.

33. Winickoff JP, Tanski SE, McMillen RC, et al. Child health care clinicians’ use of medications to help parents quit smoking: a national parent survey. Pediatrics 2005;115:1013–7.

34. Kaiser Family Foundation. Status of state action on the medicaid expansion decision. Available at http://kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/.

35. U.S. Department of Health and Human Services. The health consequences of smoking- 50 years of progress: a report of the Surgeon General. 2014.

36. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Public policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:998–1007.

37. Collins BN, Levin KP, Bryant-Stephens T. Pediatricians’ practices and attitudes about environmental tobacco smoke and parental smoking. J Pediatr 2007;150:547–52.

38. Leininger LS, Finn L, Dickey L, et al. An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Arch Fam Med 1996;5:108–15.

39. Swartz SH, Hays JT. Office-based intervention for tobacco dependence. Med Clin North Am 2004;88:1623–41.

40. Bordley WC, Margolis PA, Stuart J, et al. Improving preventive service delivery through office systems. Pediatrics 2001;108:E41.

41. Schoen C, Osborn R, Huynh PT, et al. On the front lines of care: primary care doctors’ office systems, experiences, and views in seven countries. Health Aff (Millwood) 25:w555–w71.

42. Rigotti NA, Quinn VP, Stevens VJ, et al. Tobacco-control policies in 11 leading managed care organizations: progress and challenges. Eff Clin Pract 2002;5:130–6.

43. Curry SJ. Organizational interventions to encourage guideline implementation. Chest 2000;118(2 Suppl):40S–6S.

44. Berg M, Meijerink Y, Gras M, et al. Feasibility first: developing public performance indicators on patient safety and clinical effectiveness for Dutch hospitals. Health Policy 2005;75:59–73.

45. Gandhi TK, Puopolo a L, Dasse P, et al. Obstacles to collaborative quality improvement: the case of ambulatory general medical care. Int J Qual Health Care 2000;12:115–23.

46. Mol A. Proving or improving: on health care research as a form of self-reflection. Qual Health Res 2006;16:405–14.

Issue
Journal of Clinical Outcomes Management - February 2016, VOL. 23, NO. 2
Publications
Topics
Sections

From the Massachusetts General Hospital for Children, Boston, MA (Walters, Drehmer, Nabi-Burza, Winickoff), the University of Rochester School of Medicine, Rochester, NY (Ossip), and the American Academy of Pediatrics Julius B. Richmond Center of Excellence, Elk Grove Village, IL (Whitmore, Gorzkowski). Deceased 31 December 2015.

 

Abstract

  • Background: Family tobacco use and exposure are significant threats to the health of children and their families. However, few pediatric clinicians address family tobacco use and exposure in a routine and effective manner. The Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice.
  • Objective: To review the main considerations and questions that clinicians and office staff expressed during telephone training to participate in CEASE.
  • Methods: This study was conducted in pediatric practices in 5 US states. Practices were recruited by the American Academy of Pediatrics (10 intervention, 10 control). Ten training calls were recorded and transcribed. The data was then coded inductively based on themes found in the transcripts.
  • Results: The data revealed that clinicians and staff were concerned about prescribing, dosing, and insurance coverage of nicotine replacement therapy; motivation for and methods to help families become tobacco-free; and the impact of the intervention on practice operations.
  • Conclusion: While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco-free, they expressed concerns that could threaten implementation of family tobacco control strategies.

 

 

The devastating health consequences of smoking and exposure to tobacco smoke have been well demonstrated. As declared in the 2006 Surgeon General’s Report, there is no safe level of exposure to tobacco [1]. Children are especially at risk for exposure to toxins and toxicants in tobacco smoke [1,2]. Exposure to tobacco smoke is associated with higher levels of asthma, increased risk of sudden infant death syndrome, increased rates of upper respiratory infections, and behavioral issues [3–5]. Recent research shows that over 70% of children in the United States have some level of exposure to tobacco smoke [6]; parents and other family members are commonly the cause of this exposure, especially in young children. Children and parents benefit when parents stop smoking; parent life expectancy increases by an average of 7 years [7], the risk of tobacco-related poor pregnancy outcomes is reduced, and future children are spared from exposure to tobacco smoke [8].

There is a growing movement to address tobacco use and exposure in the pediatric office setting; the 2015 American Academy of Pediatrics tobacco policy statement Clinical Practice Policy to Protect Children From Tobacco, Nicotine, and Tobacco Smoke recommends that pediatricians ask about children’s exposure to tobacco and address parental tobacco use by implementing office-wide systems to deliver advice, counseling, referral to cessation resources, and smoking cessation medication to smokers [9].

Despite significant risks of tobacco smoke exposure to children, we found in a previous paper that only 3.5% of parents in control practices received any tobacco control assistance [10]. Through a systematic and ongoing line of research, the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice. The CEASE intervention has been successfully shown to train and equip pediatric officesfrom a distance to address family tobacco use within existing office systems [10–14]. An enhanced CEASE intervention is undergoing testing in pediatric practices in 5 US states.

The CEASE intervention works with pediatric primary care offices on strategies to promote routine and effective family-centered tobacco control by addressing parental smoking and establishing smoke-free home and car rules. Based on national guidelines and extensive data obtained in previous pilot testing [12,14–16], elements of the CEASE intervention have been designed to be adapted to individual practices’ staffing, resources, and physical configuration. The main elements of the intervention are identifying tobacco users and children exposed to tobacco smoke through the use of a paper or an electronic tablet screening tool, assisting smokers in setting a quit date, establishing rules for smoke-free homes and cars, prescribing nicotine replacement therapy (NRT) to help smokers cut down or quit [17,18], referring smokers to tobacco quitlines and/or the SmokeFreeTXT program [19–25], and following up with tobacco users. Clinicians and staff are trained in the adoption, implementation, and maintenance of family-centered tobacco control strategies with the goal of embedding the elements of CEASE intervention into routine practice beyond the training and/or research study periods. The CEASE training was designed to meet the needs of pediatric offices, be time- and cost-effective, and be implemented through distance learning strategies to save both trainer and pediatric office staff resources. The training approach consists of a number of evidence-based strategies. As depicted in the Table, the training involves multiple modalities, including videos, reference materials, online computer education modules, and telephone training calls.

One of the more innovative aspects of CEASE has been the use of training calls. In studies of CEASE, the peer-to-peer call was conducted by the principal investigator with the project leader at the practice using a train-the-trainer model. After the project leader was trained through the peer-to-peer call, the project leader then led the whole office training call, with the support of CEASE staff by phone. The training calls worked in conjunction with the other aspects of the training, as shown in the Table. The training calls for the practices provided a valuable research opportunity. We examined the concerns and issues that clinicians and office staff had about implementing an office-wide tobacco control program through a qualitative analysis of the call transcripts. This paper outlines the main considerations and questions that clinicians and office staff expressed during the training calls. Understanding the points of view of clinicians and staff will help researchers and clinical educators strengthen the design of tobacco control interventions.

Methods

Study Aims

The data for this paper were collected as part of a larger mixed-methods controlled trial. The overarching aims of the trial were to study implementation and sustainability of tobacco-control services delivered at the clinic level, to facilitate behavior change among parents and evaluate cost-per-quit among parents who smoke, and to study systems changes and the processes that affect them at the practice level. The study was conducted in 5 intervention and 5 control pediatric primary care practices in 5 states; this paper reports on data collected in intervention practices and focuses on understanding the systems changes and processes that are instituted when implementing a tobacco control program at the clinician and practice level.

Practice Recruitment and Eligibility

Practices were recruited through the American Academy of Pediatrics using direct emails, newsletter/listserv articles, phone calls to members, and in-person recruitment at national meetings. Eligible practices were located in a non–hospital-based setting, had an average patient flow of at least 50 patients per day, used an electronic medical record (EMR) system, and were matched in each state based on practice size and smoking rate. Interested practices also had to be willing to host a research assistant to collect exit interview data from parents. Practices were excluded if they took part in previous CEASE studies or were actively enrolling participants into other tobacco control research studies. Based on these criteria, 18 eligible practices from Indiana, North Carolina, Ohio, Tennessee, Michigan, and Virginia agreed to participate in the study. Of the 6 states, one state was chosen as a replacement state. Five practices from the remaining states were assigned to the intervention group, 5 to the control group, and 5 were assigned to the replacement group in case an intervention or control practice in their state withdrew from the study. Each intervention practice participated in a peer-to-peer training call and a whole office training call. Data analyzed in this paper was collected from all 10 intervention practice training calls.

Training Calls Data Collection

The peer-to-peer and whole office training calls were recorded and transcribed. Permission to record the calls was requested by the trainer (the principal investigator of the study) and given verbally by each person being trained. The training call recordings were then transcribed verbatim by a commercial service; the transcriptions were spot-checked for accuracy.

The transcripts were first read closely by the first author (BHW), then coded inductively into relevant themes that emerged from the calls. The inductive coding was guided by the questions and concerns that the clinicians raised during the training, as well as the ways in which the trainer addressed these concerns and tailored the training to the needs and interests of the pediatric clinicians [26]. The coding was reviewed and confirmed by the other study team members.

 

 

After the data were coded into themes, the coded data were analyzed by the first author using qualitative description. Qualitative description is a method of analyzing coded qualitative data by looking at the words and meanings expressed by respondents [27]. Through this method of analysis, we were able to understand what concerns the clinicians and staff voiced about aspects of the CEASE intervention.

Ethics

The study was approved institutional review boards at Massachusetts General Hospital, the AAP, and the health care practices that required local IRB approval. The quotes used in this paper have been anonymized and cleaned to remove any identifying information, such as location and names.

Peer-to-Peer Training Calls

The peer-to-peer training calls were conducted after training and study materials arrived. The project leader (a pediatrician in the practice who was interested in spearheading the CEASE intervention) was asked to watch the training video. Using an evidence-based, previously developed call script [28], the principal investigator trained the project leader in key aspects of addressing family tobacco use and exposure, such as using an electronic tablet screener survey to identify family members who smoke, exploring techniques for prescribing or recommending NRT, and identifying ways to connect family members to free tobacco cessation counseling and support services. On occasion, other staff from the pediatric office (eg, a nurse or office manager) joined the call.

The principal investigator presented information, clarified points in the video, explained the materials, and asked questions and elicited relevant experiences from the project leader. In addition to teaching the project leader about the tobacco control strategies used in CEASE, the peer-to-peer calls prepared the project leader to train the rest of their own practice clinicians and staff in the CEASE intervention.

Whole Office Training Calls

Each practice’s local project leader led the whole office training calls, but CEASE study staff were on the call to introduce themselves to office staff, answer any questions that staff may have raised that the project leader could not answer, give information about data collection, and to generally support the implementation of the CEASE intervention and research program. During this call, the project leader watched the video with the group and tailored the training for his or her practice, focusing on issues of relevance for patients and staff.

Training Calls as Research Data

As many practices struggle with research burden [29], finding innovative and unobtrusive methods of collecting data is especially useful for research teams and participating practices. During both calls, clinicians and staff were asked open-ended questions to learn about their concerns regarding intervention implementation, share their own experiences with tobacco and tobacco control, and explore practice-specific methods to address family smoking. CEASE staff used this opportunity to help practices tailor the intervention to the local setting, such as by offering quitline enrollment sheets in another language. Clinician and staff answers to open-ended questions provided qualitative data for this manuscript.

Results and Discussion

The research team used training call data to explore clinician and staff concerns and desires related to family-centered tobacco control. The most common themes were: (1) prescribing, dosing, and insurance coverage of NRT, (2) motivation for and methods to help families become tobacco-free, and (3) the impact of the CEASE intervention on the day-to-day operations of the practice.

Nicotine Replacement Therapy

Prescribing or recommending NRT is one of the best ways to help families become tobacco-free and is a crucial component of the CEASE intervention [30–32]. Through the telephone trainings, clinicians and staff were trained to prescribe NRT using pre-printed prescription sheets, presented information about the effectiveness of NRT for smoking cessation, and referred to an information sheet on NRT to answer other questions as needed.

During the calls, it became clear that the pediatric clinicians were interested in prescribing NRT to help smokers quit, but lacked the skills and knowledge to do so:

I’m writing all this down [about NRT], because I don’t know any of this. (IN peer-to-peer)

Is 4 mg the strongest the gum comes in? (NC whole office)

This lack of knowledge may be a barrier to prescribing NRT in the pediatric setting. A national survey revealed that while smoking parents would accept prescriptions for NRT from their child’s doctor, very few received a prescription [33]. The calls provided an opportunity to have clinicians’ questions about NRT be answered by a pediatric tobacco control expert.

Clinicians were interested in helping parents stop smoking with medication, but were worried about access to medication; one of the most common questions voiced was not about how or why to prescribe NRT but how to help low-income parents get NRT for free or low-cost.

Some people—they don’t have insurance, so, how much it costs, they need to know that. (TN peer-to-peer)

I just know I’ve got a bunch ... Obamacare doesn’t work down here, so—I’ve still got families who don’t have any insurance, and you’re like, “Oh, I was hoping you could get something,” and they’re like, “Well, we can’t.” I have a fair number of kids who—are on some type of insurance, but the parents don’t have any coverage for NRT. (VA peer-to-peer)

While NRT is covered under the Affordable Care Act, many states have not expanded their Medicaid coverage [34]; this leaves many low-income families without access to health insurance or to free or low-cost NRT. While NRT remains one of the best and most common smoking cessation tools [35] there was no way to reassure practices that parents would be able to obtain the prescribed NRT without guaranteed coverage. In a previous study, the cost of NRT was seen by smokers as a barrier to using NRT to quit smoking [32]. Clinicians’ concerns about the cost of NRT reveal an understanding of the needs and issues relevant to their patient population.

Motivation for and Methods to Help Families Become Tobacco-Free

Clinicians and office staff were motivated to help families become tobacco-free and were interested in various ways to do so. The motivation and interest were personal, clinical, and organizational, relating to the ways in which care in the pediatric office could be altered to address tobacco in a more systematic way.

 

 

Motivation

The interest in smoking cessation stems from the desire to protect children from the harmful effects tobacco smoke and to prevent children themselves from taking up smoking:

We’d always talked about the smoking, and the parents finally quit. Probably not like I helped them—I just had been harping on them—but by that point the boy was smoking. When he was little he was like, “Oh, that’s nasty. I can’t believe my parents smoke.” Then by the time he was 14-15 and the parents actually did manage to quit, he was smoking, and I was like, “Ugh, really?” (VA peer-to-peer)

I totally understand the dire need for this project, in both the tobacco in the households, as well as the teenagers smoking. I heard one stat[istic], that one of our high schools had 80% of children using tobacco products… And that’s on my watch… I understand and I share the same passion that you do, for personal reasons, as well as reasons to help the whole community. (NC peer-to-peer)

Pediatricians saw themselves as responsible for protecting children’s health through reducing their tobacco smoke exposure, for working to prevent teen smoking, and for the overall health of their communities. Helping prevent childhood exposure to tobacco smoke and teen smoking initiation are crucial tasks for pediatricians; the 2015 AAP tobacco policy statement strongly recommends that pediatric offices include tobacco use prevention messages when talking to children and teens to help prevent smoking initiation, as well as helping families establish smoking bans for homes and cars [36]. By participating in the CEASE telephone trainings, clinicians and office staff were learning skills and tools to help them act on their motivation to protect families from the harms of tobacco.

Strategies

Pediatricians and office staff were interested in learning specific strategies and tools to help parents stop smoking. Practices wanted to know how and when to set a quit date with families, how to use services to help families become smoke-free, and how to tailor assistance to specific populations.

Yeah, we’re wondering about other languages, because we do have a large Hispanic patient population and a sizable group of folks that come from Saudi Arabia, and I know that some of them do smoke. (TN peer-to-peer)

Set[ting] a quit date for the patient —so how long we want to set the date? 6 months, 3 months, 1 year, 2 years, what? (TN peer-to-peer)

If you have a mom who lives with grandma and grandpa, the mom may not smoke but grandma and grandpa smoke, but they still live in that home… But anyone who comes in, we’re going to help. Does that sound right? (VA peer-to-peer)

By participating in the study, the clinicians and office staff were actively seeking to improve their knowledge of tobacco-related issues; past research has shown that pediatric residents saw lack of training in tobacco control as a key reason for inconsistent tobacco control outreach and intervention [37]. The training calls were an opportunity to gain information more specifically related to the pediatric practice’s population and office setting, building upon the other CEASE training materials. The training calls were also a chance for the CEASE research team to adapt strategies and tools to the practices, for example by providing materials that met the practices’ needs.

Impact of Intervention on Day-To-Day Operations

The training calls revealed that integrating CEASE into office workflows was a major concern. Integrating preventive services into routine office practice is a frequent concern of primary care providers [38–41]. These concerns about office flow reflect worries about financing [42] and benchmarking [43–45].

I think they’re going to have some of the same questions [that I initially had] in terms of how this might work with workflow. But as we’ve talked through all of this, I think we can make it work, and make it just sort of incorporated as part of our everyday questions that we ask. And it shouldn’t really slow things down. And I think that’ll be the main thing the providers would be focusing on is, how’s this going to impact me and all the other things I have to do in the course of a visit? This [phone call] answers a lot of questions I had in terms of that. (IN peer-to-peer)

As wait time was a performance measure for many of the practices, the clinicians and staff were hesitant to add any activities to check-in that might increase wait time.

I know, so especially, we’re trying to do a care team right now... don’t want them to spend too much time in the waiting room. (OH whole office)

During the calls, clinicians and office staff were asked to reflect on their practices and discuss ways that their practice would implement the CEASE intervention. This moment of reflection is a benefit of research participation, as it allows practices to improve the care they provide [46]. The calls allowed for on-the-spot tailoring of the intervention to meet the specific needs of the practice, an opportunity for the research staff and practice to work together to make the intervention fit their particular office situation and flow. Data collected from the training calls were also reviewed during the CEASE implementation process to support practices with specific concerns.

Strengths and Limitations

As these data were collected during training calls and subject to social desirability bias, the concerns raised may not be an exhaustive list of all concerns that clinicians and office staff had. However, the concerns that were raised by clinicians became a natural and essential part of the training process. As the practices’ initial concerns were identified early in the study, it was possible to address these concerns throughout the early implementation phases of CEASE. Transcribing calls and analyzing training call data as quickly as possible during the training phases of an intervention could prove beneficial for strengthening the implementation.

Dedicating the extra time and effort to record the training calls as a source of data formalized and strengthened the implementation process. By recording training calls, the study team was able to document the practices’ concerns and share them among the research team, including those who were not on training calls. This effort was a significant source of quality improvement data for the research team and helped ensure that we were responsive to the articulated needs of clinicians and practices.

 

 

Conclusion

The training call data revealed both the concerns as well as the interests of child health care clinicians in regard to addressing family tobacco use. While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco free, they expressed concerns that could threaten full implementation of family tobacco control strategies. These concerns and interests related to the coverage and affordability of NRT, integrating tobacco control strategies into the practice flow, and learning strategies to address family-wide tobacco use, such as helping grandparents quit smoking or addressing tobacco use with those who were not native English speakers. The concerns and interests of clinicians and office staff revealed that they were genuinely interested in learning ways to tailor strategies to address tobacco use for their practices and patient populations. By recording the training calls, the study team was better able to help them tailor the intervention to their practice, both during the calls and during subsequent implementation by providing new materials and additional information on subjects of concern to the practice. Carefully documenting training calls with health care practices are an ideal opportunity to collect information on issues that may impact full implementation of future interventions.

Corresponding author: Jonathan P. Winickoff, jwinickoff@mgh.harvard.edu

From the Massachusetts General Hospital for Children, Boston, MA (Walters, Drehmer, Nabi-Burza, Winickoff), the University of Rochester School of Medicine, Rochester, NY (Ossip), and the American Academy of Pediatrics Julius B. Richmond Center of Excellence, Elk Grove Village, IL (Whitmore, Gorzkowski). Deceased 31 December 2015.

 

Abstract

  • Background: Family tobacco use and exposure are significant threats to the health of children and their families. However, few pediatric clinicians address family tobacco use and exposure in a routine and effective manner. The Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice.
  • Objective: To review the main considerations and questions that clinicians and office staff expressed during telephone training to participate in CEASE.
  • Methods: This study was conducted in pediatric practices in 5 US states. Practices were recruited by the American Academy of Pediatrics (10 intervention, 10 control). Ten training calls were recorded and transcribed. The data was then coded inductively based on themes found in the transcripts.
  • Results: The data revealed that clinicians and staff were concerned about prescribing, dosing, and insurance coverage of nicotine replacement therapy; motivation for and methods to help families become tobacco-free; and the impact of the intervention on practice operations.
  • Conclusion: While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco-free, they expressed concerns that could threaten implementation of family tobacco control strategies.

 

 

The devastating health consequences of smoking and exposure to tobacco smoke have been well demonstrated. As declared in the 2006 Surgeon General’s Report, there is no safe level of exposure to tobacco [1]. Children are especially at risk for exposure to toxins and toxicants in tobacco smoke [1,2]. Exposure to tobacco smoke is associated with higher levels of asthma, increased risk of sudden infant death syndrome, increased rates of upper respiratory infections, and behavioral issues [3–5]. Recent research shows that over 70% of children in the United States have some level of exposure to tobacco smoke [6]; parents and other family members are commonly the cause of this exposure, especially in young children. Children and parents benefit when parents stop smoking; parent life expectancy increases by an average of 7 years [7], the risk of tobacco-related poor pregnancy outcomes is reduced, and future children are spared from exposure to tobacco smoke [8].

There is a growing movement to address tobacco use and exposure in the pediatric office setting; the 2015 American Academy of Pediatrics tobacco policy statement Clinical Practice Policy to Protect Children From Tobacco, Nicotine, and Tobacco Smoke recommends that pediatricians ask about children’s exposure to tobacco and address parental tobacco use by implementing office-wide systems to deliver advice, counseling, referral to cessation resources, and smoking cessation medication to smokers [9].

Despite significant risks of tobacco smoke exposure to children, we found in a previous paper that only 3.5% of parents in control practices received any tobacco control assistance [10]. Through a systematic and ongoing line of research, the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention was developed to tackle this gap between clinical need and clinical practice. The CEASE intervention has been successfully shown to train and equip pediatric officesfrom a distance to address family tobacco use within existing office systems [10–14]. An enhanced CEASE intervention is undergoing testing in pediatric practices in 5 US states.

The CEASE intervention works with pediatric primary care offices on strategies to promote routine and effective family-centered tobacco control by addressing parental smoking and establishing smoke-free home and car rules. Based on national guidelines and extensive data obtained in previous pilot testing [12,14–16], elements of the CEASE intervention have been designed to be adapted to individual practices’ staffing, resources, and physical configuration. The main elements of the intervention are identifying tobacco users and children exposed to tobacco smoke through the use of a paper or an electronic tablet screening tool, assisting smokers in setting a quit date, establishing rules for smoke-free homes and cars, prescribing nicotine replacement therapy (NRT) to help smokers cut down or quit [17,18], referring smokers to tobacco quitlines and/or the SmokeFreeTXT program [19–25], and following up with tobacco users. Clinicians and staff are trained in the adoption, implementation, and maintenance of family-centered tobacco control strategies with the goal of embedding the elements of CEASE intervention into routine practice beyond the training and/or research study periods. The CEASE training was designed to meet the needs of pediatric offices, be time- and cost-effective, and be implemented through distance learning strategies to save both trainer and pediatric office staff resources. The training approach consists of a number of evidence-based strategies. As depicted in the Table, the training involves multiple modalities, including videos, reference materials, online computer education modules, and telephone training calls.

One of the more innovative aspects of CEASE has been the use of training calls. In studies of CEASE, the peer-to-peer call was conducted by the principal investigator with the project leader at the practice using a train-the-trainer model. After the project leader was trained through the peer-to-peer call, the project leader then led the whole office training call, with the support of CEASE staff by phone. The training calls worked in conjunction with the other aspects of the training, as shown in the Table. The training calls for the practices provided a valuable research opportunity. We examined the concerns and issues that clinicians and office staff had about implementing an office-wide tobacco control program through a qualitative analysis of the call transcripts. This paper outlines the main considerations and questions that clinicians and office staff expressed during the training calls. Understanding the points of view of clinicians and staff will help researchers and clinical educators strengthen the design of tobacco control interventions.

Methods

Study Aims

The data for this paper were collected as part of a larger mixed-methods controlled trial. The overarching aims of the trial were to study implementation and sustainability of tobacco-control services delivered at the clinic level, to facilitate behavior change among parents and evaluate cost-per-quit among parents who smoke, and to study systems changes and the processes that affect them at the practice level. The study was conducted in 5 intervention and 5 control pediatric primary care practices in 5 states; this paper reports on data collected in intervention practices and focuses on understanding the systems changes and processes that are instituted when implementing a tobacco control program at the clinician and practice level.

Practice Recruitment and Eligibility

Practices were recruited through the American Academy of Pediatrics using direct emails, newsletter/listserv articles, phone calls to members, and in-person recruitment at national meetings. Eligible practices were located in a non–hospital-based setting, had an average patient flow of at least 50 patients per day, used an electronic medical record (EMR) system, and were matched in each state based on practice size and smoking rate. Interested practices also had to be willing to host a research assistant to collect exit interview data from parents. Practices were excluded if they took part in previous CEASE studies or were actively enrolling participants into other tobacco control research studies. Based on these criteria, 18 eligible practices from Indiana, North Carolina, Ohio, Tennessee, Michigan, and Virginia agreed to participate in the study. Of the 6 states, one state was chosen as a replacement state. Five practices from the remaining states were assigned to the intervention group, 5 to the control group, and 5 were assigned to the replacement group in case an intervention or control practice in their state withdrew from the study. Each intervention practice participated in a peer-to-peer training call and a whole office training call. Data analyzed in this paper was collected from all 10 intervention practice training calls.

Training Calls Data Collection

The peer-to-peer and whole office training calls were recorded and transcribed. Permission to record the calls was requested by the trainer (the principal investigator of the study) and given verbally by each person being trained. The training call recordings were then transcribed verbatim by a commercial service; the transcriptions were spot-checked for accuracy.

The transcripts were first read closely by the first author (BHW), then coded inductively into relevant themes that emerged from the calls. The inductive coding was guided by the questions and concerns that the clinicians raised during the training, as well as the ways in which the trainer addressed these concerns and tailored the training to the needs and interests of the pediatric clinicians [26]. The coding was reviewed and confirmed by the other study team members.

 

 

After the data were coded into themes, the coded data were analyzed by the first author using qualitative description. Qualitative description is a method of analyzing coded qualitative data by looking at the words and meanings expressed by respondents [27]. Through this method of analysis, we were able to understand what concerns the clinicians and staff voiced about aspects of the CEASE intervention.

Ethics

The study was approved institutional review boards at Massachusetts General Hospital, the AAP, and the health care practices that required local IRB approval. The quotes used in this paper have been anonymized and cleaned to remove any identifying information, such as location and names.

Peer-to-Peer Training Calls

The peer-to-peer training calls were conducted after training and study materials arrived. The project leader (a pediatrician in the practice who was interested in spearheading the CEASE intervention) was asked to watch the training video. Using an evidence-based, previously developed call script [28], the principal investigator trained the project leader in key aspects of addressing family tobacco use and exposure, such as using an electronic tablet screener survey to identify family members who smoke, exploring techniques for prescribing or recommending NRT, and identifying ways to connect family members to free tobacco cessation counseling and support services. On occasion, other staff from the pediatric office (eg, a nurse or office manager) joined the call.

The principal investigator presented information, clarified points in the video, explained the materials, and asked questions and elicited relevant experiences from the project leader. In addition to teaching the project leader about the tobacco control strategies used in CEASE, the peer-to-peer calls prepared the project leader to train the rest of their own practice clinicians and staff in the CEASE intervention.

Whole Office Training Calls

Each practice’s local project leader led the whole office training calls, but CEASE study staff were on the call to introduce themselves to office staff, answer any questions that staff may have raised that the project leader could not answer, give information about data collection, and to generally support the implementation of the CEASE intervention and research program. During this call, the project leader watched the video with the group and tailored the training for his or her practice, focusing on issues of relevance for patients and staff.

Training Calls as Research Data

As many practices struggle with research burden [29], finding innovative and unobtrusive methods of collecting data is especially useful for research teams and participating practices. During both calls, clinicians and staff were asked open-ended questions to learn about their concerns regarding intervention implementation, share their own experiences with tobacco and tobacco control, and explore practice-specific methods to address family smoking. CEASE staff used this opportunity to help practices tailor the intervention to the local setting, such as by offering quitline enrollment sheets in another language. Clinician and staff answers to open-ended questions provided qualitative data for this manuscript.

Results and Discussion

The research team used training call data to explore clinician and staff concerns and desires related to family-centered tobacco control. The most common themes were: (1) prescribing, dosing, and insurance coverage of NRT, (2) motivation for and methods to help families become tobacco-free, and (3) the impact of the CEASE intervention on the day-to-day operations of the practice.

Nicotine Replacement Therapy

Prescribing or recommending NRT is one of the best ways to help families become tobacco-free and is a crucial component of the CEASE intervention [30–32]. Through the telephone trainings, clinicians and staff were trained to prescribe NRT using pre-printed prescription sheets, presented information about the effectiveness of NRT for smoking cessation, and referred to an information sheet on NRT to answer other questions as needed.

During the calls, it became clear that the pediatric clinicians were interested in prescribing NRT to help smokers quit, but lacked the skills and knowledge to do so:

I’m writing all this down [about NRT], because I don’t know any of this. (IN peer-to-peer)

Is 4 mg the strongest the gum comes in? (NC whole office)

This lack of knowledge may be a barrier to prescribing NRT in the pediatric setting. A national survey revealed that while smoking parents would accept prescriptions for NRT from their child’s doctor, very few received a prescription [33]. The calls provided an opportunity to have clinicians’ questions about NRT be answered by a pediatric tobacco control expert.

Clinicians were interested in helping parents stop smoking with medication, but were worried about access to medication; one of the most common questions voiced was not about how or why to prescribe NRT but how to help low-income parents get NRT for free or low-cost.

Some people—they don’t have insurance, so, how much it costs, they need to know that. (TN peer-to-peer)

I just know I’ve got a bunch ... Obamacare doesn’t work down here, so—I’ve still got families who don’t have any insurance, and you’re like, “Oh, I was hoping you could get something,” and they’re like, “Well, we can’t.” I have a fair number of kids who—are on some type of insurance, but the parents don’t have any coverage for NRT. (VA peer-to-peer)

While NRT is covered under the Affordable Care Act, many states have not expanded their Medicaid coverage [34]; this leaves many low-income families without access to health insurance or to free or low-cost NRT. While NRT remains one of the best and most common smoking cessation tools [35] there was no way to reassure practices that parents would be able to obtain the prescribed NRT without guaranteed coverage. In a previous study, the cost of NRT was seen by smokers as a barrier to using NRT to quit smoking [32]. Clinicians’ concerns about the cost of NRT reveal an understanding of the needs and issues relevant to their patient population.

Motivation for and Methods to Help Families Become Tobacco-Free

Clinicians and office staff were motivated to help families become tobacco-free and were interested in various ways to do so. The motivation and interest were personal, clinical, and organizational, relating to the ways in which care in the pediatric office could be altered to address tobacco in a more systematic way.

 

 

Motivation

The interest in smoking cessation stems from the desire to protect children from the harmful effects tobacco smoke and to prevent children themselves from taking up smoking:

We’d always talked about the smoking, and the parents finally quit. Probably not like I helped them—I just had been harping on them—but by that point the boy was smoking. When he was little he was like, “Oh, that’s nasty. I can’t believe my parents smoke.” Then by the time he was 14-15 and the parents actually did manage to quit, he was smoking, and I was like, “Ugh, really?” (VA peer-to-peer)

I totally understand the dire need for this project, in both the tobacco in the households, as well as the teenagers smoking. I heard one stat[istic], that one of our high schools had 80% of children using tobacco products… And that’s on my watch… I understand and I share the same passion that you do, for personal reasons, as well as reasons to help the whole community. (NC peer-to-peer)

Pediatricians saw themselves as responsible for protecting children’s health through reducing their tobacco smoke exposure, for working to prevent teen smoking, and for the overall health of their communities. Helping prevent childhood exposure to tobacco smoke and teen smoking initiation are crucial tasks for pediatricians; the 2015 AAP tobacco policy statement strongly recommends that pediatric offices include tobacco use prevention messages when talking to children and teens to help prevent smoking initiation, as well as helping families establish smoking bans for homes and cars [36]. By participating in the CEASE telephone trainings, clinicians and office staff were learning skills and tools to help them act on their motivation to protect families from the harms of tobacco.

Strategies

Pediatricians and office staff were interested in learning specific strategies and tools to help parents stop smoking. Practices wanted to know how and when to set a quit date with families, how to use services to help families become smoke-free, and how to tailor assistance to specific populations.

Yeah, we’re wondering about other languages, because we do have a large Hispanic patient population and a sizable group of folks that come from Saudi Arabia, and I know that some of them do smoke. (TN peer-to-peer)

Set[ting] a quit date for the patient —so how long we want to set the date? 6 months, 3 months, 1 year, 2 years, what? (TN peer-to-peer)

If you have a mom who lives with grandma and grandpa, the mom may not smoke but grandma and grandpa smoke, but they still live in that home… But anyone who comes in, we’re going to help. Does that sound right? (VA peer-to-peer)

By participating in the study, the clinicians and office staff were actively seeking to improve their knowledge of tobacco-related issues; past research has shown that pediatric residents saw lack of training in tobacco control as a key reason for inconsistent tobacco control outreach and intervention [37]. The training calls were an opportunity to gain information more specifically related to the pediatric practice’s population and office setting, building upon the other CEASE training materials. The training calls were also a chance for the CEASE research team to adapt strategies and tools to the practices, for example by providing materials that met the practices’ needs.

Impact of Intervention on Day-To-Day Operations

The training calls revealed that integrating CEASE into office workflows was a major concern. Integrating preventive services into routine office practice is a frequent concern of primary care providers [38–41]. These concerns about office flow reflect worries about financing [42] and benchmarking [43–45].

I think they’re going to have some of the same questions [that I initially had] in terms of how this might work with workflow. But as we’ve talked through all of this, I think we can make it work, and make it just sort of incorporated as part of our everyday questions that we ask. And it shouldn’t really slow things down. And I think that’ll be the main thing the providers would be focusing on is, how’s this going to impact me and all the other things I have to do in the course of a visit? This [phone call] answers a lot of questions I had in terms of that. (IN peer-to-peer)

As wait time was a performance measure for many of the practices, the clinicians and staff were hesitant to add any activities to check-in that might increase wait time.

I know, so especially, we’re trying to do a care team right now... don’t want them to spend too much time in the waiting room. (OH whole office)

During the calls, clinicians and office staff were asked to reflect on their practices and discuss ways that their practice would implement the CEASE intervention. This moment of reflection is a benefit of research participation, as it allows practices to improve the care they provide [46]. The calls allowed for on-the-spot tailoring of the intervention to meet the specific needs of the practice, an opportunity for the research staff and practice to work together to make the intervention fit their particular office situation and flow. Data collected from the training calls were also reviewed during the CEASE implementation process to support practices with specific concerns.

Strengths and Limitations

As these data were collected during training calls and subject to social desirability bias, the concerns raised may not be an exhaustive list of all concerns that clinicians and office staff had. However, the concerns that were raised by clinicians became a natural and essential part of the training process. As the practices’ initial concerns were identified early in the study, it was possible to address these concerns throughout the early implementation phases of CEASE. Transcribing calls and analyzing training call data as quickly as possible during the training phases of an intervention could prove beneficial for strengthening the implementation.

Dedicating the extra time and effort to record the training calls as a source of data formalized and strengthened the implementation process. By recording training calls, the study team was able to document the practices’ concerns and share them among the research team, including those who were not on training calls. This effort was a significant source of quality improvement data for the research team and helped ensure that we were responsive to the articulated needs of clinicians and practices.

 

 

Conclusion

The training call data revealed both the concerns as well as the interests of child health care clinicians in regard to addressing family tobacco use. While the majority of clinicians and office staff were interested and enthusiastic about helping families become tobacco free, they expressed concerns that could threaten full implementation of family tobacco control strategies. These concerns and interests related to the coverage and affordability of NRT, integrating tobacco control strategies into the practice flow, and learning strategies to address family-wide tobacco use, such as helping grandparents quit smoking or addressing tobacco use with those who were not native English speakers. The concerns and interests of clinicians and office staff revealed that they were genuinely interested in learning ways to tailor strategies to address tobacco use for their practices and patient populations. By recording the training calls, the study team was better able to help them tailor the intervention to their practice, both during the calls and during subsequent implementation by providing new materials and additional information on subjects of concern to the practice. Carefully documenting training calls with health care practices are an ideal opportunity to collect information on issues that may impact full implementation of future interventions.

Corresponding author: Jonathan P. Winickoff, jwinickoff@mgh.harvard.edu

References

1. U.S. Department of Health and Human Services. The health consequences of involuntary tobacco smoke: a report of the Surgeon General. 2006.

2. Rauh VA, Whyatt RM, Garfinkel R, et al. Developmental effects of exposure to environmental tobacco smoke and material hardship among inner-city children. Neurotoxicol Teratol 2004;26:373–85.

3. Polanska K, Hanke W, Ronchetti R, et al. Environmental tobacco smoke exposure and children’s health. Acta Paediatr Suppl 2006;95:86–92.

4. American Academy of Pediatrics, Committee on Substance Abuse. Tobacco’s toll: implications for the pediatrician. Pediatrics 2001;107:794–8.

5. U.S. Department of Health and Human Services. Children and secondhand smoke exposure. Excerpts from the health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon GeneralAtlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health2007.

6. Wilson KM, Klein JD, Blumkin AK, et al. Tobacco-smoke exposure in children who live in multiunit housing. Pediatrics 2011;127:85–92.

7. Taylor SM, Ross NA, Cummings KM, et al. Community intervention trial for smoking cessation (COMMIT): changes in community attitudes toward cigarette smoking. Health Educ Res 1998;13:109-22.

8. Winickoff JP, Healey EA, Regan S, et al. Using the postpartum hospital stay to address mothers’ and fathers’ smoking: the NEWS study. Pediatrics 2010;125:518–25.

9. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Clinical practice policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:1008–17.

10. Winickoff JP, Nabi-Burza E, Chang Y, et al. Implementation of a parental tobacco control intervention in pediatric practice. Pediatrics 2013;132:109–17.

11. Ossip DJ, Chang Y, Nabi-Burza E, et al. Strict smoke-free home policies among smoking parents in pediatric settings. Acad Pediatr 2013;13:517–23.

12. Winickoff JP, Park ER, Hipple BJ, et al. Clinical effort against secondhand smoke exposure: development of framework and intervention. Pediatrics 2008;122:e363–e75.

13. Nabi-Burza E, Winickoff JP, Finch S, Regan S. Triple tobacco screen: opportunity to help families become smokefree. Am J Prev Med 2013;45:728–31.

14. Winickoff JP. Pediatrician-led program increases provision of smoking cessation support, boosts quit rates among parents. Innovations in Medicine 2011. Accessed 24 Nov 2015 at https://innovations.ahrq.gov/profiles/pediatrician-led-program-increases-provision-smoking-cessation-support-boosts-quit-rates.

15. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.

16. Winickoff JP, Nabi-Burza E, Chang Y, et al. Sustainability of a parental tobacco control intervention in pediatric practice. Pediatrics 2014;134:933-41.

17. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.

18. Aveyard P, Wang D, Connock M, et al. Assessing the outcomes of prolonged cessation-induction and aid-to-cessation trials: floating prolonged abstinence. Nicotine Tob Res 2009;11:475–80.

19. Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011;36:764–8.

20.Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998;339:673–9.

21. Abroms LC, Ahuja M, Kodl Y, et al. Text2Quit: Results from a pilot test of a personalized, interactive mobile health smoking cessation program. J Health Commun 2012;17 Suppl 1:44-53.

22. Curry SJ, Ludman EJ, Graham E, et al. Pediatric-based smoking cessation intervention for low-income women: a randomized trial. Arch Pediatr Adolesc Med 2003;157:295–302.

23. Orleans CT, Schoenbach VJ, Wagner EH. Self-help quit smoking interventions: effects of self-help materials, social support materials, social support instructions and telephone counseling. J Consult Clin Psychol 1991;59:439–48.

24. An LC, Zhu SH, Nelson DB, et al. Benefits of telephone care over primary care for smoking cessation: a randomized trial. Arch Intern Med 2006;166:536–42.

25. Warner DO, Klesges RC, Dale LC, et al. Clinician-delivered intervention to facilitate tobacco quitline use by surgical patients. Anesthesiology 2011;114:847–55.

26. Creswell, JW. Qualitative inquiry and research design: choosing among five approaches. 2nd ed. Thousand Oaks, CA: Sage; 2007.

27. Sandelowski M. Focus on research methods: whatever happened to qualitative description. Res Nurs Health 2000;23:334–40.

28. Winickoff JP, Hipple B, Drehmer J, et al. The clinical effort against secondhand smoke exposure (CEASE) intervention: A decade of lessons learned. J Clin Outcomes Manag 2012;19:414–9.

29. Clark T, Sinclair R. The costs and benefits of acting as a research site. Evid Policy A J Res Debate Pract 2008;4:105–19.

30. Zhu S, Melcer T, Sun J. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305–11.

31. Gilpin EA, Messer K, Pierce JP. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res 2006;8:661–9.

32. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med 2005;28:119–22.

33. Winickoff JP, Tanski SE, McMillen RC, et al. Child health care clinicians’ use of medications to help parents quit smoking: a national parent survey. Pediatrics 2005;115:1013–7.

34. Kaiser Family Foundation. Status of state action on the medicaid expansion decision. Available at http://kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/.

35. U.S. Department of Health and Human Services. The health consequences of smoking- 50 years of progress: a report of the Surgeon General. 2014.

36. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Public policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:998–1007.

37. Collins BN, Levin KP, Bryant-Stephens T. Pediatricians’ practices and attitudes about environmental tobacco smoke and parental smoking. J Pediatr 2007;150:547–52.

38. Leininger LS, Finn L, Dickey L, et al. An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Arch Fam Med 1996;5:108–15.

39. Swartz SH, Hays JT. Office-based intervention for tobacco dependence. Med Clin North Am 2004;88:1623–41.

40. Bordley WC, Margolis PA, Stuart J, et al. Improving preventive service delivery through office systems. Pediatrics 2001;108:E41.

41. Schoen C, Osborn R, Huynh PT, et al. On the front lines of care: primary care doctors’ office systems, experiences, and views in seven countries. Health Aff (Millwood) 25:w555–w71.

42. Rigotti NA, Quinn VP, Stevens VJ, et al. Tobacco-control policies in 11 leading managed care organizations: progress and challenges. Eff Clin Pract 2002;5:130–6.

43. Curry SJ. Organizational interventions to encourage guideline implementation. Chest 2000;118(2 Suppl):40S–6S.

44. Berg M, Meijerink Y, Gras M, et al. Feasibility first: developing public performance indicators on patient safety and clinical effectiveness for Dutch hospitals. Health Policy 2005;75:59–73.

45. Gandhi TK, Puopolo a L, Dasse P, et al. Obstacles to collaborative quality improvement: the case of ambulatory general medical care. Int J Qual Health Care 2000;12:115–23.

46. Mol A. Proving or improving: on health care research as a form of self-reflection. Qual Health Res 2006;16:405–14.

References

1. U.S. Department of Health and Human Services. The health consequences of involuntary tobacco smoke: a report of the Surgeon General. 2006.

2. Rauh VA, Whyatt RM, Garfinkel R, et al. Developmental effects of exposure to environmental tobacco smoke and material hardship among inner-city children. Neurotoxicol Teratol 2004;26:373–85.

3. Polanska K, Hanke W, Ronchetti R, et al. Environmental tobacco smoke exposure and children’s health. Acta Paediatr Suppl 2006;95:86–92.

4. American Academy of Pediatrics, Committee on Substance Abuse. Tobacco’s toll: implications for the pediatrician. Pediatrics 2001;107:794–8.

5. U.S. Department of Health and Human Services. Children and secondhand smoke exposure. Excerpts from the health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon GeneralAtlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health2007.

6. Wilson KM, Klein JD, Blumkin AK, et al. Tobacco-smoke exposure in children who live in multiunit housing. Pediatrics 2011;127:85–92.

7. Taylor SM, Ross NA, Cummings KM, et al. Community intervention trial for smoking cessation (COMMIT): changes in community attitudes toward cigarette smoking. Health Educ Res 1998;13:109-22.

8. Winickoff JP, Healey EA, Regan S, et al. Using the postpartum hospital stay to address mothers’ and fathers’ smoking: the NEWS study. Pediatrics 2010;125:518–25.

9. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Clinical practice policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:1008–17.

10. Winickoff JP, Nabi-Burza E, Chang Y, et al. Implementation of a parental tobacco control intervention in pediatric practice. Pediatrics 2013;132:109–17.

11. Ossip DJ, Chang Y, Nabi-Burza E, et al. Strict smoke-free home policies among smoking parents in pediatric settings. Acad Pediatr 2013;13:517–23.

12. Winickoff JP, Park ER, Hipple BJ, et al. Clinical effort against secondhand smoke exposure: development of framework and intervention. Pediatrics 2008;122:e363–e75.

13. Nabi-Burza E, Winickoff JP, Finch S, Regan S. Triple tobacco screen: opportunity to help families become smokefree. Am J Prev Med 2013;45:728–31.

14. Winickoff JP. Pediatrician-led program increases provision of smoking cessation support, boosts quit rates among parents. Innovations in Medicine 2011. Accessed 24 Nov 2015 at https://innovations.ahrq.gov/profiles/pediatrician-led-program-increases-provision-smoking-cessation-support-boosts-quit-rates.

15. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.

16. Winickoff JP, Nabi-Burza E, Chang Y, et al. Sustainability of a parental tobacco control intervention in pediatric practice. Pediatrics 2014;134:933-41.

17. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024.

18. Aveyard P, Wang D, Connock M, et al. Assessing the outcomes of prolonged cessation-induction and aid-to-cessation trials: floating prolonged abstinence. Nicotine Tob Res 2009;11:475–80.

19. Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav 2011;36:764–8.

20.Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998;339:673–9.

21. Abroms LC, Ahuja M, Kodl Y, et al. Text2Quit: Results from a pilot test of a personalized, interactive mobile health smoking cessation program. J Health Commun 2012;17 Suppl 1:44-53.

22. Curry SJ, Ludman EJ, Graham E, et al. Pediatric-based smoking cessation intervention for low-income women: a randomized trial. Arch Pediatr Adolesc Med 2003;157:295–302.

23. Orleans CT, Schoenbach VJ, Wagner EH. Self-help quit smoking interventions: effects of self-help materials, social support materials, social support instructions and telephone counseling. J Consult Clin Psychol 1991;59:439–48.

24. An LC, Zhu SH, Nelson DB, et al. Benefits of telephone care over primary care for smoking cessation: a randomized trial. Arch Intern Med 2006;166:536–42.

25. Warner DO, Klesges RC, Dale LC, et al. Clinician-delivered intervention to facilitate tobacco quitline use by surgical patients. Anesthesiology 2011;114:847–55.

26. Creswell, JW. Qualitative inquiry and research design: choosing among five approaches. 2nd ed. Thousand Oaks, CA: Sage; 2007.

27. Sandelowski M. Focus on research methods: whatever happened to qualitative description. Res Nurs Health 2000;23:334–40.

28. Winickoff JP, Hipple B, Drehmer J, et al. The clinical effort against secondhand smoke exposure (CEASE) intervention: A decade of lessons learned. J Clin Outcomes Manag 2012;19:414–9.

29. Clark T, Sinclair R. The costs and benefits of acting as a research site. Evid Policy A J Res Debate Pract 2008;4:105–19.

30. Zhu S, Melcer T, Sun J. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305–11.

31. Gilpin EA, Messer K, Pierce JP. Population effectiveness of pharmaceutical aids for smoking cessation: what is associated with increased success? Nicotine Tob Res 2006;8:661–9.

32. Cokkinides VE, Ward E, Jemal A, Thun MJ. Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med 2005;28:119–22.

33. Winickoff JP, Tanski SE, McMillen RC, et al. Child health care clinicians’ use of medications to help parents quit smoking: a national parent survey. Pediatrics 2005;115:1013–7.

34. Kaiser Family Foundation. Status of state action on the medicaid expansion decision. Available at http://kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/.

35. U.S. Department of Health and Human Services. The health consequences of smoking- 50 years of progress: a report of the Surgeon General. 2014.

36. American Academy of Pediatrics, Section on Tobacco Control. Policy statement: Public policy to protect children from tobacco, nicotine, and tobacco smoke. Pediatrics 2015;136:998–1007.

37. Collins BN, Levin KP, Bryant-Stephens T. Pediatricians’ practices and attitudes about environmental tobacco smoke and parental smoking. J Pediatr 2007;150:547–52.

38. Leininger LS, Finn L, Dickey L, et al. An office system for organizing preventive services: a report by the American Cancer Society Advisory Group on Preventive Health Care Reminder Systems. Arch Fam Med 1996;5:108–15.

39. Swartz SH, Hays JT. Office-based intervention for tobacco dependence. Med Clin North Am 2004;88:1623–41.

40. Bordley WC, Margolis PA, Stuart J, et al. Improving preventive service delivery through office systems. Pediatrics 2001;108:E41.

41. Schoen C, Osborn R, Huynh PT, et al. On the front lines of care: primary care doctors’ office systems, experiences, and views in seven countries. Health Aff (Millwood) 25:w555–w71.

42. Rigotti NA, Quinn VP, Stevens VJ, et al. Tobacco-control policies in 11 leading managed care organizations: progress and challenges. Eff Clin Pract 2002;5:130–6.

43. Curry SJ. Organizational interventions to encourage guideline implementation. Chest 2000;118(2 Suppl):40S–6S.

44. Berg M, Meijerink Y, Gras M, et al. Feasibility first: developing public performance indicators on patient safety and clinical effectiveness for Dutch hospitals. Health Policy 2005;75:59–73.

45. Gandhi TK, Puopolo a L, Dasse P, et al. Obstacles to collaborative quality improvement: the case of ambulatory general medical care. Int J Qual Health Care 2000;12:115–23.

46. Mol A. Proving or improving: on health care research as a form of self-reflection. Qual Health Res 2006;16:405–14.

Issue
Journal of Clinical Outcomes Management - February 2016, VOL. 23, NO. 2
Issue
Journal of Clinical Outcomes Management - February 2016, VOL. 23, NO. 2
Publications
Publications
Topics
Article Type
Display Headline
Clinician Telephone Training to Reduce Family Tobacco Use: Analysis of Transcribed Recordings
Display Headline
Clinician Telephone Training to Reduce Family Tobacco Use: Analysis of Transcribed Recordings
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Induction ALL treatment can cause bone loss

Article Type
Changed
Display Headline
Induction ALL treatment can cause bone loss

Light micrograph

of cancellous bone

Patients with acute lymphoblastic leukemia (ALL) may experience significant bone loss much earlier than previously assumed, according to a study published in the journal Bone.

Investigators analyzed a cohort of adolescent and young adult ALL patients before and after their first month of chemotherapy and observed “significant alterations” to cancellous and cortical bone in this short period of time.

Previous studies to determine the changes to bone density during ALL therapy had focused on the cumulative effects of chemotherapy after months or even years of treatment.

“In clinic, we would see patients with fractures and vertebral compression during the very first few weeks of treatment,” said study author Etan Orgel, MD, of Children’s Hospital Los Angeles in California.

“But we were unaware of any study that specifically examined bone before chemotherapy and immediately after the first 30 days of treatment, which would allow us to understand the impact of this early treatment phase.”

So Dr Orgel and his colleagues conducted a prospective study of 38 patients, ages 10 to 21, who were newly diagnosed with ALL.

The team used quantitative computerized tomography (QCT) to assess leukemia-related changes to bone at diagnosis and then the subsequent effects of the induction phase of chemotherapy.

All of the patients received a 28-day induction regimen consisting of vincristine, pegylated L-asparaginase, anthracycline (daunorubicin or doxorubicin), and a glucocorticoid (either prednisone at 60 mg/m2/day for 28 days or dexamethasone at 10 mg/m2/day for 14 days).

The investigators compared the patients to age- and sex-matched controls and found that leukemia did not dramatically alter the properties of bone before chemotherapy.

However, QCT revealed significant changes during the 30-day induction phase in the 35 patients who were well enough to undergo imaging after treatment.

The patients experienced a significant decrease in cancellous volumetric bone mineral density, which was measured in the spine. The median decrease was 27% (P<0.001).

There was no significant change in cortical volumetric bone mineral density, which was measured in the tibia (−0.0%, P=0.860) or femur (−0.7%, P=0.290).

But there was significant cortical thinning in the tibia. The average cortical thickness decreased 1.2% (P<0.001), and the cortical area decreased 0.4% (P=0.014).

The femur was less affected, the investigators said. There was a decrease in average cortical thickness, but this was not significant (-0.3%, P=0.740).

To help clinicians relate to these findings, the investigators also measured bone mineral density using the older but more widely available technique of dual-energy x-ray absorptiometry. They found that it underestimated these changes as compared to QCT measurements.

“Now that we know how soon bone toxicity occurs, we need to re-evaluate our approaches to managing these changes and focus research efforts on new ways to mitigate this common yet significant adverse effect,” said study author Steven Mittelman, MD, PhD, of Children’s Hospital Los Angeles.

Publications
Topics

Light micrograph

of cancellous bone

Patients with acute lymphoblastic leukemia (ALL) may experience significant bone loss much earlier than previously assumed, according to a study published in the journal Bone.

Investigators analyzed a cohort of adolescent and young adult ALL patients before and after their first month of chemotherapy and observed “significant alterations” to cancellous and cortical bone in this short period of time.

Previous studies to determine the changes to bone density during ALL therapy had focused on the cumulative effects of chemotherapy after months or even years of treatment.

“In clinic, we would see patients with fractures and vertebral compression during the very first few weeks of treatment,” said study author Etan Orgel, MD, of Children’s Hospital Los Angeles in California.

“But we were unaware of any study that specifically examined bone before chemotherapy and immediately after the first 30 days of treatment, which would allow us to understand the impact of this early treatment phase.”

So Dr Orgel and his colleagues conducted a prospective study of 38 patients, ages 10 to 21, who were newly diagnosed with ALL.

The team used quantitative computerized tomography (QCT) to assess leukemia-related changes to bone at diagnosis and then the subsequent effects of the induction phase of chemotherapy.

All of the patients received a 28-day induction regimen consisting of vincristine, pegylated L-asparaginase, anthracycline (daunorubicin or doxorubicin), and a glucocorticoid (either prednisone at 60 mg/m2/day for 28 days or dexamethasone at 10 mg/m2/day for 14 days).

The investigators compared the patients to age- and sex-matched controls and found that leukemia did not dramatically alter the properties of bone before chemotherapy.

However, QCT revealed significant changes during the 30-day induction phase in the 35 patients who were well enough to undergo imaging after treatment.

The patients experienced a significant decrease in cancellous volumetric bone mineral density, which was measured in the spine. The median decrease was 27% (P<0.001).

There was no significant change in cortical volumetric bone mineral density, which was measured in the tibia (−0.0%, P=0.860) or femur (−0.7%, P=0.290).

But there was significant cortical thinning in the tibia. The average cortical thickness decreased 1.2% (P<0.001), and the cortical area decreased 0.4% (P=0.014).

The femur was less affected, the investigators said. There was a decrease in average cortical thickness, but this was not significant (-0.3%, P=0.740).

To help clinicians relate to these findings, the investigators also measured bone mineral density using the older but more widely available technique of dual-energy x-ray absorptiometry. They found that it underestimated these changes as compared to QCT measurements.

“Now that we know how soon bone toxicity occurs, we need to re-evaluate our approaches to managing these changes and focus research efforts on new ways to mitigate this common yet significant adverse effect,” said study author Steven Mittelman, MD, PhD, of Children’s Hospital Los Angeles.

Light micrograph

of cancellous bone

Patients with acute lymphoblastic leukemia (ALL) may experience significant bone loss much earlier than previously assumed, according to a study published in the journal Bone.

Investigators analyzed a cohort of adolescent and young adult ALL patients before and after their first month of chemotherapy and observed “significant alterations” to cancellous and cortical bone in this short period of time.

Previous studies to determine the changes to bone density during ALL therapy had focused on the cumulative effects of chemotherapy after months or even years of treatment.

“In clinic, we would see patients with fractures and vertebral compression during the very first few weeks of treatment,” said study author Etan Orgel, MD, of Children’s Hospital Los Angeles in California.

“But we were unaware of any study that specifically examined bone before chemotherapy and immediately after the first 30 days of treatment, which would allow us to understand the impact of this early treatment phase.”

So Dr Orgel and his colleagues conducted a prospective study of 38 patients, ages 10 to 21, who were newly diagnosed with ALL.

The team used quantitative computerized tomography (QCT) to assess leukemia-related changes to bone at diagnosis and then the subsequent effects of the induction phase of chemotherapy.

All of the patients received a 28-day induction regimen consisting of vincristine, pegylated L-asparaginase, anthracycline (daunorubicin or doxorubicin), and a glucocorticoid (either prednisone at 60 mg/m2/day for 28 days or dexamethasone at 10 mg/m2/day for 14 days).

The investigators compared the patients to age- and sex-matched controls and found that leukemia did not dramatically alter the properties of bone before chemotherapy.

However, QCT revealed significant changes during the 30-day induction phase in the 35 patients who were well enough to undergo imaging after treatment.

The patients experienced a significant decrease in cancellous volumetric bone mineral density, which was measured in the spine. The median decrease was 27% (P<0.001).

There was no significant change in cortical volumetric bone mineral density, which was measured in the tibia (−0.0%, P=0.860) or femur (−0.7%, P=0.290).

But there was significant cortical thinning in the tibia. The average cortical thickness decreased 1.2% (P<0.001), and the cortical area decreased 0.4% (P=0.014).

The femur was less affected, the investigators said. There was a decrease in average cortical thickness, but this was not significant (-0.3%, P=0.740).

To help clinicians relate to these findings, the investigators also measured bone mineral density using the older but more widely available technique of dual-energy x-ray absorptiometry. They found that it underestimated these changes as compared to QCT measurements.

“Now that we know how soon bone toxicity occurs, we need to re-evaluate our approaches to managing these changes and focus research efforts on new ways to mitigate this common yet significant adverse effect,” said study author Steven Mittelman, MD, PhD, of Children’s Hospital Los Angeles.

Publications
Publications
Topics
Article Type
Display Headline
Induction ALL treatment can cause bone loss
Display Headline
Induction ALL treatment can cause bone loss
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Aripiprazole may suppress prolactin in boys who develop gynecomasta while on risperidon, other atypical antipsychotics

Article Type
Changed
Display Headline
Aripiprazole may suppress prolactin in boys who develop gynecomasta while on risperidon, other atypical antipsychotics

NEW YORK – In adolescent boys who develop gynecomastia while taking an atypical antipsychotic that elevates prolactin, extra steps should be taken to confirm that it is drug related, according to a review of data presented at a psychopharmacology update held by the American Academy of Child and Adolescent Psychiatry.

“In 13- to 14-year-old boys who develop gynecomastia while taking risperidone, the odds of it being due to pubertal gynecomastia rather than risperidone are about 15:1,” reported Dr. Harold E. Carlson, division head of endocrinology, State University of New York at Stony Brook.

Ted Bosworth/Frontline Medical News
Dr. Harold E. Carlson

Hyperprolactinemia is associated with a variety of adverse effects on normal physiology, resulting in osteoporosis, decreased libido, erectile dysfunction in men, and amenorrhea and possibly hirsutism in women, Dr. Carlson said. However, he cautioned that clinicians should not assume that breast enlargement in peripubertal children is a result of elevated prolactin.

“Remember that nearly all boys who take drugs like risperidone will have an elevated serum prolactin at least early on, and then it will come down,” Dr. Carlson said. “But the data say that 3%-5% will get gynecomastia on risperidone, which means that 95%-97% of people taking risperidone don’t get gynecomastia,”

Most cases of gynecomastia in boys on risperidone are unrelated to the medication. “Pubertal gynecomastia has nothing to do with prolactin. It is a phenomenon that occurs in normal puberty,” Dr. Carlson emphasized. The pubertal breast enlargement was once considered most likely to be produced by a transient imbalance in the sex steroids, but Dr. Carlson said that recent studies have linked this phenomenon to insulinlike growth factor I (IGF-I). This is supported by several sets of data, said Dr. Carlson, who also noted, “teenage boys have the highest IGF-I levels of anybody.”

The data suggest that normal physiology is a more likely cause of breast enlargement in pubertal boys than an antipsychotic drug that raises prolactin, but Dr. Carlson said clinicians should educate patients and parents about the risk. 

In a boy or a girl who reports breast tenderness that appears to be glandular rather than adipose on palpation, Dr. Carlson suggested measuring serum prolactin levels. If prolactin levels are greater than 30 ng/mL, an alternative, prolactin-neutral therapy, is “prudent,” he said. He showed data in which a switch from risperidone or ziprasidone to quetiapine produced large reductions in serum prolactin within 3 months.

Another strategy, which is useful when there is concern about discontinuing a prolactin-raising antipsychotic, is to add aripiprazole, which suppresses prolactin. “Aripiprazole doses of 5-15 mg per day are often effective in normalizing serum prolactin in patients receiving haloperidol, risperidone, paliperidone, or olanzapine,” Dr. Carlson said, However, he noted that it is “not as effective in lowering serum prolactin in patients receiving amisulpride or sulpiride.”

Prolonged periods of hyperprolactinemia can produce adverse effects in boys and girls, but those effects are “generally reversible if the underlying problem is corrected within 1-2 years,” Dr. Carlson said. In adolescents on prolactin-elevating drugs, however, it is important to demonstrate rather than assume that elevated prolactin is the cause of symptoms. It also is important to consider all causes of hyperprolactinemia, which can include impaired thyroid or kidney function.

“Inquire about menstruation, breast enlargement or tenderness, nipple discharge, sexual functioning, and pubertal development,” Dr. Carlson advised. “If normal, there is no need to measure serum prolactin.”

Dr. Carlson reported financial relationships with Lundbeck and Pfizer.

*This story was updated on Feb. 24, 2016.

References

Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
Palpable Glandular issue, Gynecomastia, Antipsychotics
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

NEW YORK – In adolescent boys who develop gynecomastia while taking an atypical antipsychotic that elevates prolactin, extra steps should be taken to confirm that it is drug related, according to a review of data presented at a psychopharmacology update held by the American Academy of Child and Adolescent Psychiatry.

“In 13- to 14-year-old boys who develop gynecomastia while taking risperidone, the odds of it being due to pubertal gynecomastia rather than risperidone are about 15:1,” reported Dr. Harold E. Carlson, division head of endocrinology, State University of New York at Stony Brook.

Ted Bosworth/Frontline Medical News
Dr. Harold E. Carlson

Hyperprolactinemia is associated with a variety of adverse effects on normal physiology, resulting in osteoporosis, decreased libido, erectile dysfunction in men, and amenorrhea and possibly hirsutism in women, Dr. Carlson said. However, he cautioned that clinicians should not assume that breast enlargement in peripubertal children is a result of elevated prolactin.

“Remember that nearly all boys who take drugs like risperidone will have an elevated serum prolactin at least early on, and then it will come down,” Dr. Carlson said. “But the data say that 3%-5% will get gynecomastia on risperidone, which means that 95%-97% of people taking risperidone don’t get gynecomastia,”

Most cases of gynecomastia in boys on risperidone are unrelated to the medication. “Pubertal gynecomastia has nothing to do with prolactin. It is a phenomenon that occurs in normal puberty,” Dr. Carlson emphasized. The pubertal breast enlargement was once considered most likely to be produced by a transient imbalance in the sex steroids, but Dr. Carlson said that recent studies have linked this phenomenon to insulinlike growth factor I (IGF-I). This is supported by several sets of data, said Dr. Carlson, who also noted, “teenage boys have the highest IGF-I levels of anybody.”

The data suggest that normal physiology is a more likely cause of breast enlargement in pubertal boys than an antipsychotic drug that raises prolactin, but Dr. Carlson said clinicians should educate patients and parents about the risk. 

In a boy or a girl who reports breast tenderness that appears to be glandular rather than adipose on palpation, Dr. Carlson suggested measuring serum prolactin levels. If prolactin levels are greater than 30 ng/mL, an alternative, prolactin-neutral therapy, is “prudent,” he said. He showed data in which a switch from risperidone or ziprasidone to quetiapine produced large reductions in serum prolactin within 3 months.

Another strategy, which is useful when there is concern about discontinuing a prolactin-raising antipsychotic, is to add aripiprazole, which suppresses prolactin. “Aripiprazole doses of 5-15 mg per day are often effective in normalizing serum prolactin in patients receiving haloperidol, risperidone, paliperidone, or olanzapine,” Dr. Carlson said, However, he noted that it is “not as effective in lowering serum prolactin in patients receiving amisulpride or sulpiride.”

Prolonged periods of hyperprolactinemia can produce adverse effects in boys and girls, but those effects are “generally reversible if the underlying problem is corrected within 1-2 years,” Dr. Carlson said. In adolescents on prolactin-elevating drugs, however, it is important to demonstrate rather than assume that elevated prolactin is the cause of symptoms. It also is important to consider all causes of hyperprolactinemia, which can include impaired thyroid or kidney function.

“Inquire about menstruation, breast enlargement or tenderness, nipple discharge, sexual functioning, and pubertal development,” Dr. Carlson advised. “If normal, there is no need to measure serum prolactin.”

Dr. Carlson reported financial relationships with Lundbeck and Pfizer.

*This story was updated on Feb. 24, 2016.

NEW YORK – In adolescent boys who develop gynecomastia while taking an atypical antipsychotic that elevates prolactin, extra steps should be taken to confirm that it is drug related, according to a review of data presented at a psychopharmacology update held by the American Academy of Child and Adolescent Psychiatry.

“In 13- to 14-year-old boys who develop gynecomastia while taking risperidone, the odds of it being due to pubertal gynecomastia rather than risperidone are about 15:1,” reported Dr. Harold E. Carlson, division head of endocrinology, State University of New York at Stony Brook.

Ted Bosworth/Frontline Medical News
Dr. Harold E. Carlson

Hyperprolactinemia is associated with a variety of adverse effects on normal physiology, resulting in osteoporosis, decreased libido, erectile dysfunction in men, and amenorrhea and possibly hirsutism in women, Dr. Carlson said. However, he cautioned that clinicians should not assume that breast enlargement in peripubertal children is a result of elevated prolactin.

“Remember that nearly all boys who take drugs like risperidone will have an elevated serum prolactin at least early on, and then it will come down,” Dr. Carlson said. “But the data say that 3%-5% will get gynecomastia on risperidone, which means that 95%-97% of people taking risperidone don’t get gynecomastia,”

Most cases of gynecomastia in boys on risperidone are unrelated to the medication. “Pubertal gynecomastia has nothing to do with prolactin. It is a phenomenon that occurs in normal puberty,” Dr. Carlson emphasized. The pubertal breast enlargement was once considered most likely to be produced by a transient imbalance in the sex steroids, but Dr. Carlson said that recent studies have linked this phenomenon to insulinlike growth factor I (IGF-I). This is supported by several sets of data, said Dr. Carlson, who also noted, “teenage boys have the highest IGF-I levels of anybody.”

The data suggest that normal physiology is a more likely cause of breast enlargement in pubertal boys than an antipsychotic drug that raises prolactin, but Dr. Carlson said clinicians should educate patients and parents about the risk. 

In a boy or a girl who reports breast tenderness that appears to be glandular rather than adipose on palpation, Dr. Carlson suggested measuring serum prolactin levels. If prolactin levels are greater than 30 ng/mL, an alternative, prolactin-neutral therapy, is “prudent,” he said. He showed data in which a switch from risperidone or ziprasidone to quetiapine produced large reductions in serum prolactin within 3 months.

Another strategy, which is useful when there is concern about discontinuing a prolactin-raising antipsychotic, is to add aripiprazole, which suppresses prolactin. “Aripiprazole doses of 5-15 mg per day are often effective in normalizing serum prolactin in patients receiving haloperidol, risperidone, paliperidone, or olanzapine,” Dr. Carlson said, However, he noted that it is “not as effective in lowering serum prolactin in patients receiving amisulpride or sulpiride.”

Prolonged periods of hyperprolactinemia can produce adverse effects in boys and girls, but those effects are “generally reversible if the underlying problem is corrected within 1-2 years,” Dr. Carlson said. In adolescents on prolactin-elevating drugs, however, it is important to demonstrate rather than assume that elevated prolactin is the cause of symptoms. It also is important to consider all causes of hyperprolactinemia, which can include impaired thyroid or kidney function.

“Inquire about menstruation, breast enlargement or tenderness, nipple discharge, sexual functioning, and pubertal development,” Dr. Carlson advised. “If normal, there is no need to measure serum prolactin.”

Dr. Carlson reported financial relationships with Lundbeck and Pfizer.

*This story was updated on Feb. 24, 2016.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Aripiprazole may suppress prolactin in boys who develop gynecomasta while on risperidon, other atypical antipsychotics
Display Headline
Aripiprazole may suppress prolactin in boys who develop gynecomasta while on risperidon, other atypical antipsychotics
Legacy Keywords
Palpable Glandular issue, Gynecomastia, Antipsychotics
Legacy Keywords
Palpable Glandular issue, Gynecomastia, Antipsychotics
Article Source

EXPERT ANALYSIS FROM THE PSYCHOPHARMACOLOGY UPDATE INSTITUTE

PURLs Copyright

Inside the Article

A bone to pick

Article Type
Changed
Display Headline
A bone to pick

I have had a long and circuitous relationship with the radius. When I was 9 years old, I slipped on the wet grass of our front yard in an attempt to make a highlight-reel baseball catch and landed awkwardly on my left arm. After I continued to complain for a day and a half, my mother took me to see our pediatrician, Dr. Blum. After feeling up and down my forearm and asking me to squeeze his fingers, he pronounced me well.

A week and a half later, when I was still favoring what is my dominant arm, we returned to Dr. Blum. Apparently still unimpressed with my physical exam, he begrudgingly ordered an x-ray. Hurrah! I had a fracture! But then he announced that we would treat it with a splint and an ace wrap. Come on! Everyone knows that if you break a bone you get a cast. From then on he was Dr. Bum to me.

Dr. William G. Wilkoff

For the next 2 weeks, I was forbidden to play sports, meanwhile losing serious credibility points with my peers who suspected that I was a wimp and had fabricated the whole story. And of course, does anyone go around asking their friends to sign his ace wrap ... really? It took me years of overcompensation to regain even a hint of preteen machismo.

During my last year of medical school, I leapt at the opportunity to take an elective in pediatric orthopedics. It was great! With coaching from the residents, I learned when to suspect a buckle fracture of the radius, identify it on x-ray, and best of all, how to apply a cast.

When I finally entered practice here in Brunswick, we were seriously short of specialists, including orthopedists. When it was discovered that I knew how to apply a forearm cast, the orthopedists encouraged me to treat my own patients with simple forearm fractures. They were more than busy enough with really exciting stuff.

As an artist at heart, the chance to mold in plaster and plastic was a special treat. I took great pride in my creations, and making a beautiful crafted cast was sometimes the high point of my day. No splints or wimpy ace wraps for my patients!

Parents loved the one-stop shopping. History, exam, x-ray, casting, and out the door in less than an hour. Because I was the only primary care physician in town who was casting fractures, I occasionally had to remind the emergency room physicians to send me my patients with buckle fractures instead of knee-jerking a referral to an orthopedist.

But then about 10 years ago, some party-pooping orthopedists from who-knows-where looked at a very large series of pediatric patients with buckle fractures of the radius and discovered that those patients treated with splints had at least as good results as those who had been casted. And ... the patients and parents preferred the splints. I had to admit that maybe Dr. Blum wasn’t such a bum after all. Sadly, I had to respond to the evidence by giving up my hobby except when a child’s temperament or past history of injury suggested that he or she might benefit from the extra protection a cast could afford.

A recent study from Toronto published in Pediatrics, “Primary Care Physician Follow-up of Distal Radius Buckle Fractures,” by Koelink et al., makes me wonder whether a splint and ace wrap may even be overtreatment (Pediatrics. 2016 Jan;137[1]:11-9. doi: 10.1542/peds.2015-2262). In this review of 200 pediatric patients with distal radius buckle fractures, the investigators found that regardless of whether the primary care physician discussed how long to use the splint or when to return to activity, more than two-thirds of the patients wore their splints less than 3 weeks. Despite what the authors considered suboptimal primary care physician guidance, 99% of the patients returned to usual activities within 4 weeks.

My mother and Dr. Blum were on the right track from the beginning. They just needed to ignore my complaints a few days longer.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics including “How to Say No to Your Toddler.”

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
simple forearm fracture, bucke radius fractures, xrays
Sections
Author and Disclosure Information

Author and Disclosure Information

I have had a long and circuitous relationship with the radius. When I was 9 years old, I slipped on the wet grass of our front yard in an attempt to make a highlight-reel baseball catch and landed awkwardly on my left arm. After I continued to complain for a day and a half, my mother took me to see our pediatrician, Dr. Blum. After feeling up and down my forearm and asking me to squeeze his fingers, he pronounced me well.

A week and a half later, when I was still favoring what is my dominant arm, we returned to Dr. Blum. Apparently still unimpressed with my physical exam, he begrudgingly ordered an x-ray. Hurrah! I had a fracture! But then he announced that we would treat it with a splint and an ace wrap. Come on! Everyone knows that if you break a bone you get a cast. From then on he was Dr. Bum to me.

Dr. William G. Wilkoff

For the next 2 weeks, I was forbidden to play sports, meanwhile losing serious credibility points with my peers who suspected that I was a wimp and had fabricated the whole story. And of course, does anyone go around asking their friends to sign his ace wrap ... really? It took me years of overcompensation to regain even a hint of preteen machismo.

During my last year of medical school, I leapt at the opportunity to take an elective in pediatric orthopedics. It was great! With coaching from the residents, I learned when to suspect a buckle fracture of the radius, identify it on x-ray, and best of all, how to apply a cast.

When I finally entered practice here in Brunswick, we were seriously short of specialists, including orthopedists. When it was discovered that I knew how to apply a forearm cast, the orthopedists encouraged me to treat my own patients with simple forearm fractures. They were more than busy enough with really exciting stuff.

As an artist at heart, the chance to mold in plaster and plastic was a special treat. I took great pride in my creations, and making a beautiful crafted cast was sometimes the high point of my day. No splints or wimpy ace wraps for my patients!

Parents loved the one-stop shopping. History, exam, x-ray, casting, and out the door in less than an hour. Because I was the only primary care physician in town who was casting fractures, I occasionally had to remind the emergency room physicians to send me my patients with buckle fractures instead of knee-jerking a referral to an orthopedist.

But then about 10 years ago, some party-pooping orthopedists from who-knows-where looked at a very large series of pediatric patients with buckle fractures of the radius and discovered that those patients treated with splints had at least as good results as those who had been casted. And ... the patients and parents preferred the splints. I had to admit that maybe Dr. Blum wasn’t such a bum after all. Sadly, I had to respond to the evidence by giving up my hobby except when a child’s temperament or past history of injury suggested that he or she might benefit from the extra protection a cast could afford.

A recent study from Toronto published in Pediatrics, “Primary Care Physician Follow-up of Distal Radius Buckle Fractures,” by Koelink et al., makes me wonder whether a splint and ace wrap may even be overtreatment (Pediatrics. 2016 Jan;137[1]:11-9. doi: 10.1542/peds.2015-2262). In this review of 200 pediatric patients with distal radius buckle fractures, the investigators found that regardless of whether the primary care physician discussed how long to use the splint or when to return to activity, more than two-thirds of the patients wore their splints less than 3 weeks. Despite what the authors considered suboptimal primary care physician guidance, 99% of the patients returned to usual activities within 4 weeks.

My mother and Dr. Blum were on the right track from the beginning. They just needed to ignore my complaints a few days longer.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics including “How to Say No to Your Toddler.”

I have had a long and circuitous relationship with the radius. When I was 9 years old, I slipped on the wet grass of our front yard in an attempt to make a highlight-reel baseball catch and landed awkwardly on my left arm. After I continued to complain for a day and a half, my mother took me to see our pediatrician, Dr. Blum. After feeling up and down my forearm and asking me to squeeze his fingers, he pronounced me well.

A week and a half later, when I was still favoring what is my dominant arm, we returned to Dr. Blum. Apparently still unimpressed with my physical exam, he begrudgingly ordered an x-ray. Hurrah! I had a fracture! But then he announced that we would treat it with a splint and an ace wrap. Come on! Everyone knows that if you break a bone you get a cast. From then on he was Dr. Bum to me.

Dr. William G. Wilkoff

For the next 2 weeks, I was forbidden to play sports, meanwhile losing serious credibility points with my peers who suspected that I was a wimp and had fabricated the whole story. And of course, does anyone go around asking their friends to sign his ace wrap ... really? It took me years of overcompensation to regain even a hint of preteen machismo.

During my last year of medical school, I leapt at the opportunity to take an elective in pediatric orthopedics. It was great! With coaching from the residents, I learned when to suspect a buckle fracture of the radius, identify it on x-ray, and best of all, how to apply a cast.

When I finally entered practice here in Brunswick, we were seriously short of specialists, including orthopedists. When it was discovered that I knew how to apply a forearm cast, the orthopedists encouraged me to treat my own patients with simple forearm fractures. They were more than busy enough with really exciting stuff.

As an artist at heart, the chance to mold in plaster and plastic was a special treat. I took great pride in my creations, and making a beautiful crafted cast was sometimes the high point of my day. No splints or wimpy ace wraps for my patients!

Parents loved the one-stop shopping. History, exam, x-ray, casting, and out the door in less than an hour. Because I was the only primary care physician in town who was casting fractures, I occasionally had to remind the emergency room physicians to send me my patients with buckle fractures instead of knee-jerking a referral to an orthopedist.

But then about 10 years ago, some party-pooping orthopedists from who-knows-where looked at a very large series of pediatric patients with buckle fractures of the radius and discovered that those patients treated with splints had at least as good results as those who had been casted. And ... the patients and parents preferred the splints. I had to admit that maybe Dr. Blum wasn’t such a bum after all. Sadly, I had to respond to the evidence by giving up my hobby except when a child’s temperament or past history of injury suggested that he or she might benefit from the extra protection a cast could afford.

A recent study from Toronto published in Pediatrics, “Primary Care Physician Follow-up of Distal Radius Buckle Fractures,” by Koelink et al., makes me wonder whether a splint and ace wrap may even be overtreatment (Pediatrics. 2016 Jan;137[1]:11-9. doi: 10.1542/peds.2015-2262). In this review of 200 pediatric patients with distal radius buckle fractures, the investigators found that regardless of whether the primary care physician discussed how long to use the splint or when to return to activity, more than two-thirds of the patients wore their splints less than 3 weeks. Despite what the authors considered suboptimal primary care physician guidance, 99% of the patients returned to usual activities within 4 weeks.

My mother and Dr. Blum were on the right track from the beginning. They just needed to ignore my complaints a few days longer.

Dr. Wilkoff practiced primary care pediatrics in Brunswick, Maine, for nearly 40 years. He has authored several books on behavioral pediatrics including “How to Say No to Your Toddler.”

References

References

Publications
Publications
Topics
Article Type
Display Headline
A bone to pick
Display Headline
A bone to pick
Legacy Keywords
simple forearm fracture, bucke radius fractures, xrays
Legacy Keywords
simple forearm fracture, bucke radius fractures, xrays
Sections
Article Source

PURLs Copyright

Inside the Article

Teamwork, Part 1: Should a Mental Health Specialist Be on Site?

Article Type
Changed
Display Headline
Teamwork, Part 1: Should a Mental Health Specialist Be on Site?

Dr. Lillian M. Beard discusses the challenges of getting reimbursed for providing mental and behavioral health care within her pediatric practice. Addressing her patients’ mental health needs can take three of her regular appointment times. “I am never adequately reimbursed for the time that it really takes,” she says. Having a mental health specialist on site might be one possibility, but is this model feasible? In this video, Dr. Beard, Dr. April Barbour, and Dr. Lorenzo Norris explore ways primary care and psychiatry can work together to provide patients with the best possible care.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
References

Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

Dr. Lillian M. Beard discusses the challenges of getting reimbursed for providing mental and behavioral health care within her pediatric practice. Addressing her patients’ mental health needs can take three of her regular appointment times. “I am never adequately reimbursed for the time that it really takes,” she says. Having a mental health specialist on site might be one possibility, but is this model feasible? In this video, Dr. Beard, Dr. April Barbour, and Dr. Lorenzo Norris explore ways primary care and psychiatry can work together to provide patients with the best possible care.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

Dr. Lillian M. Beard discusses the challenges of getting reimbursed for providing mental and behavioral health care within her pediatric practice. Addressing her patients’ mental health needs can take three of her regular appointment times. “I am never adequately reimbursed for the time that it really takes,” she says. Having a mental health specialist on site might be one possibility, but is this model feasible? In this video, Dr. Beard, Dr. April Barbour, and Dr. Lorenzo Norris explore ways primary care and psychiatry can work together to provide patients with the best possible care.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
References

References

Publications
Publications
Topics
Article Type
Display Headline
Teamwork, Part 1: Should a Mental Health Specialist Be on Site?
Display Headline
Teamwork, Part 1: Should a Mental Health Specialist Be on Site?
Article Source

PURLs Copyright

Inside the Article

Tdap effectiveness wanes rapidly in teens

A cough, not a whoop, in teens with pertussis
Article Type
Changed
Display Headline
Tdap effectiveness wanes rapidly in teens

The Tdap vaccine’s effectiveness against pertussis wanes so rapidly in the year after administration in teens that it provides too little protection to prevent outbreaks, according to results of a new study.

The Tdap is the booster vaccine against tetanus, diphtheria, and pertussis that adults and children ages 10 and older can receive. The corresponding acellular pertussis vaccine for children ages 6 and younger is the DTaP.

“Widespread Tdap vaccination, although associated with a transient decrease in pertussis incidence, did not prevent outbreaks among this population of teenagers who have only ever received acellular pertussis vaccines,” reported Dr. Nicola P. Klein and her associates at the Kaiser Permanente Vaccine Study Center in Oakland, Calif. “This study demonstrates that despite high rates of Tdap vaccination, the growing cohort of adolescents who have only received acellular pertussis vaccines continue to be at high risk of contracting pertussis and sustaining epidemics,” they wrote online (Pediatrics. 2016 Feb 5. [doi: 10.1542/peds.2015-3326]).

©CDC

The researchers tracked 279,493 members of Kaiser Permanente Northern California who had received only DTaP vaccines, as opposed to the whole-cell DTwP formulation previously used, from age 10 onward. These included all members who were born from 1999 onward or were born from 1996-1998 and received three infant doses of DTaP, excluding children who had previously received Tdap or had pertussis. Among these, 175,094 children received the Tdap.

For the purposes of tracking pertussis cases in unvaccinated versus vaccinated adolescents, individuals were considered unvaccinated in the analysis until they received their first Tdap, after which they were vaccinated and time since vaccination was a continuous variable. Overall, 96.5% of the children were vaccinated by their 14th birthday.

Across 792,418 person-years between January 2006 and March 2015, including 418,595 vaccinated person-years for the children who received the Tdap, 1,207 cases of pertussis occurred. The vast majority of these – 85% – occurred among those ages 10-13 years. Teens aged 14-16 years comprised 15% of the cases, and only 0.5% of cases occurred among older teens. During each year of outbreaks, incidence dropped off precipitously among the age groups composed of children who would have received the whole-cell pertussis vaccine.

For example, “pertussis incidence in the 2010 outbreak sharply declined after this peak [of 10- to 11-year-olds] and stayed low at older ages, a decline that we have previously demonstrated to be associated with the receipt of whole cell instead of acellular pertussis vaccines in infancy and childhood as well as with Tdap receipt,” the authors wrote.

The researchers estimated the Tdap’s effectiveness at 69% throughout the first year after vaccination. This dropped to 57% in the second year after vaccination and then to 25% in the third year. By 4 years or later after Tdap receipt, the vaccine’s effectiveness sat at just 9%.

For each year after Tdap vaccination, children’s risk of pertussis increased 35% (hazard ratio, 1.35), and cases were mild or moderate regardless of vaccination status. Nearly all (98%) of the children with pertussis had visited the doctor within 5 days on either side of their positive polymerase chain reaction test, 86% received a diagnosis of pertussis, and 96% received a prescription for azithromycin, except for 1 for erythromycin. In addition, 4% (50) of the cases visited the emergency department. No differences in rate of ED visits or prescriptions existed between vaccinated and unvaccinated children.

“The strategy of routinely vaccinating adolescents to prevent future disease did not prevent the 2014 epidemic, arguably because the protection afforded by a dose of Tdap was too short-lived,” the authors noted. They also pointed out that Tdap waning estimates likely also include ongoing DTaP waning.“This study was unable to disentangle the waning of Tdap effectiveness from the ongoing waning of previous doses of DTaP because the years since vaccination for Tdap and the fifth DTaP dose are closely correlated,” they wrote.

Most of the Tdap vaccines administered were Adacel (Sanofi Pasteur), but Boostrix (GlaxoSmithKline) was used as well. Waning occurred in both brands, and although not directly compared, no major differences in waning seemed to exist.

“We expect future pertussis epidemics to be larger as the cohort that has only received acellular pertussis vaccines ages,” the authors concluded. “The results in this study raise serious questions regarding the benefits of routinely administering a single dose of Tdap to every adolescent aged 11 or 12 years.”

The research was funded by Kaiser Permanente. Dr. Klein has received research funding from GlaxoSmithKline for a separate pertussis vaccine effectiveness study, and Dr. Klein and one coauthor also have received research funding from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, Novartis, Protein Science, Nuron Biotech, and MedImmune. The remaining coauthors said they had no relevant financial disclosures. GlaxoSmithKline and Sanofi Pasteur manufacture the pertussis vaccines purchased by Kaiser Permanente for this study.

References

Body

When adolescents contract whooping cough, a.k.a. pertussis, they usually don’t whoop but they cough, sometimes for 3 months. The illness is impactful for them and they are contagious to others, so the infection spreads to classmates and within families. Waning immunity after experiencing pertussis infection, after receiving the old DTwP vaccine that was discontinued in the United States years ago due to safety issues, and after receiving the newer DTaP and Tdap vaccines, has been known to occur for many years. What is new in this article is the rapidity of waning immunity in the study population.

Dr. Michael E. Pichichero

First, it is important to note that the study population is from California, a state where pertussis has been circulating much more than in most other states. The exact reasons for a higher prevalence of pertussis in California are not fully understood, but a high rate of vaccine refusers may be a significant factor. Secondly, the study uses a mathematical model, so it is an estimate of waning immunity. Nevertheless, the observations alert health care providers and the community that pertussis can occur even in vaccinated persons, especially as time passes after vaccination.

The solutions are few at this time. Public health care officials are unlikely to recommend boosters more frequently than already advocated, although that is an option. Alternative formulations of Tdap to include other or additional ingredients could be a path forward, but the vaccine industry is tackling so many new diseases with vaccine development programs that a push for a better DTaP or Tdap is unlikely in the near term.

Dr. Michael E. Pichichero, specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. Dr. Pichichero said he had no relevant financial disclosures.

Author and Disclosure Information

Publications
Topics
Legacy Keywords
Tdap vaccine, DtaP, efficacy, wanes, rapid, teens, adolescents, whooping cough, pertussis
Sections
Author and Disclosure Information

Author and Disclosure Information

Body

When adolescents contract whooping cough, a.k.a. pertussis, they usually don’t whoop but they cough, sometimes for 3 months. The illness is impactful for them and they are contagious to others, so the infection spreads to classmates and within families. Waning immunity after experiencing pertussis infection, after receiving the old DTwP vaccine that was discontinued in the United States years ago due to safety issues, and after receiving the newer DTaP and Tdap vaccines, has been known to occur for many years. What is new in this article is the rapidity of waning immunity in the study population.

Dr. Michael E. Pichichero

First, it is important to note that the study population is from California, a state where pertussis has been circulating much more than in most other states. The exact reasons for a higher prevalence of pertussis in California are not fully understood, but a high rate of vaccine refusers may be a significant factor. Secondly, the study uses a mathematical model, so it is an estimate of waning immunity. Nevertheless, the observations alert health care providers and the community that pertussis can occur even in vaccinated persons, especially as time passes after vaccination.

The solutions are few at this time. Public health care officials are unlikely to recommend boosters more frequently than already advocated, although that is an option. Alternative formulations of Tdap to include other or additional ingredients could be a path forward, but the vaccine industry is tackling so many new diseases with vaccine development programs that a push for a better DTaP or Tdap is unlikely in the near term.

Dr. Michael E. Pichichero, specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. Dr. Pichichero said he had no relevant financial disclosures.

Body

When adolescents contract whooping cough, a.k.a. pertussis, they usually don’t whoop but they cough, sometimes for 3 months. The illness is impactful for them and they are contagious to others, so the infection spreads to classmates and within families. Waning immunity after experiencing pertussis infection, after receiving the old DTwP vaccine that was discontinued in the United States years ago due to safety issues, and after receiving the newer DTaP and Tdap vaccines, has been known to occur for many years. What is new in this article is the rapidity of waning immunity in the study population.

Dr. Michael E. Pichichero

First, it is important to note that the study population is from California, a state where pertussis has been circulating much more than in most other states. The exact reasons for a higher prevalence of pertussis in California are not fully understood, but a high rate of vaccine refusers may be a significant factor. Secondly, the study uses a mathematical model, so it is an estimate of waning immunity. Nevertheless, the observations alert health care providers and the community that pertussis can occur even in vaccinated persons, especially as time passes after vaccination.

The solutions are few at this time. Public health care officials are unlikely to recommend boosters more frequently than already advocated, although that is an option. Alternative formulations of Tdap to include other or additional ingredients could be a path forward, but the vaccine industry is tackling so many new diseases with vaccine development programs that a push for a better DTaP or Tdap is unlikely in the near term.

Dr. Michael E. Pichichero, specialist in pediatric infectious diseases, is director of the Research Institute, Rochester (N.Y.) General Hospital. He is also a pediatrician at Legacy Pediatrics in Rochester. Dr. Pichichero said he had no relevant financial disclosures.

Title
A cough, not a whoop, in teens with pertussis
A cough, not a whoop, in teens with pertussis

The Tdap vaccine’s effectiveness against pertussis wanes so rapidly in the year after administration in teens that it provides too little protection to prevent outbreaks, according to results of a new study.

The Tdap is the booster vaccine against tetanus, diphtheria, and pertussis that adults and children ages 10 and older can receive. The corresponding acellular pertussis vaccine for children ages 6 and younger is the DTaP.

“Widespread Tdap vaccination, although associated with a transient decrease in pertussis incidence, did not prevent outbreaks among this population of teenagers who have only ever received acellular pertussis vaccines,” reported Dr. Nicola P. Klein and her associates at the Kaiser Permanente Vaccine Study Center in Oakland, Calif. “This study demonstrates that despite high rates of Tdap vaccination, the growing cohort of adolescents who have only received acellular pertussis vaccines continue to be at high risk of contracting pertussis and sustaining epidemics,” they wrote online (Pediatrics. 2016 Feb 5. [doi: 10.1542/peds.2015-3326]).

©CDC

The researchers tracked 279,493 members of Kaiser Permanente Northern California who had received only DTaP vaccines, as opposed to the whole-cell DTwP formulation previously used, from age 10 onward. These included all members who were born from 1999 onward or were born from 1996-1998 and received three infant doses of DTaP, excluding children who had previously received Tdap or had pertussis. Among these, 175,094 children received the Tdap.

For the purposes of tracking pertussis cases in unvaccinated versus vaccinated adolescents, individuals were considered unvaccinated in the analysis until they received their first Tdap, after which they were vaccinated and time since vaccination was a continuous variable. Overall, 96.5% of the children were vaccinated by their 14th birthday.

Across 792,418 person-years between January 2006 and March 2015, including 418,595 vaccinated person-years for the children who received the Tdap, 1,207 cases of pertussis occurred. The vast majority of these – 85% – occurred among those ages 10-13 years. Teens aged 14-16 years comprised 15% of the cases, and only 0.5% of cases occurred among older teens. During each year of outbreaks, incidence dropped off precipitously among the age groups composed of children who would have received the whole-cell pertussis vaccine.

For example, “pertussis incidence in the 2010 outbreak sharply declined after this peak [of 10- to 11-year-olds] and stayed low at older ages, a decline that we have previously demonstrated to be associated with the receipt of whole cell instead of acellular pertussis vaccines in infancy and childhood as well as with Tdap receipt,” the authors wrote.

The researchers estimated the Tdap’s effectiveness at 69% throughout the first year after vaccination. This dropped to 57% in the second year after vaccination and then to 25% in the third year. By 4 years or later after Tdap receipt, the vaccine’s effectiveness sat at just 9%.

For each year after Tdap vaccination, children’s risk of pertussis increased 35% (hazard ratio, 1.35), and cases were mild or moderate regardless of vaccination status. Nearly all (98%) of the children with pertussis had visited the doctor within 5 days on either side of their positive polymerase chain reaction test, 86% received a diagnosis of pertussis, and 96% received a prescription for azithromycin, except for 1 for erythromycin. In addition, 4% (50) of the cases visited the emergency department. No differences in rate of ED visits or prescriptions existed between vaccinated and unvaccinated children.

“The strategy of routinely vaccinating adolescents to prevent future disease did not prevent the 2014 epidemic, arguably because the protection afforded by a dose of Tdap was too short-lived,” the authors noted. They also pointed out that Tdap waning estimates likely also include ongoing DTaP waning.“This study was unable to disentangle the waning of Tdap effectiveness from the ongoing waning of previous doses of DTaP because the years since vaccination for Tdap and the fifth DTaP dose are closely correlated,” they wrote.

Most of the Tdap vaccines administered were Adacel (Sanofi Pasteur), but Boostrix (GlaxoSmithKline) was used as well. Waning occurred in both brands, and although not directly compared, no major differences in waning seemed to exist.

“We expect future pertussis epidemics to be larger as the cohort that has only received acellular pertussis vaccines ages,” the authors concluded. “The results in this study raise serious questions regarding the benefits of routinely administering a single dose of Tdap to every adolescent aged 11 or 12 years.”

The research was funded by Kaiser Permanente. Dr. Klein has received research funding from GlaxoSmithKline for a separate pertussis vaccine effectiveness study, and Dr. Klein and one coauthor also have received research funding from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, Novartis, Protein Science, Nuron Biotech, and MedImmune. The remaining coauthors said they had no relevant financial disclosures. GlaxoSmithKline and Sanofi Pasteur manufacture the pertussis vaccines purchased by Kaiser Permanente for this study.

The Tdap vaccine’s effectiveness against pertussis wanes so rapidly in the year after administration in teens that it provides too little protection to prevent outbreaks, according to results of a new study.

The Tdap is the booster vaccine against tetanus, diphtheria, and pertussis that adults and children ages 10 and older can receive. The corresponding acellular pertussis vaccine for children ages 6 and younger is the DTaP.

“Widespread Tdap vaccination, although associated with a transient decrease in pertussis incidence, did not prevent outbreaks among this population of teenagers who have only ever received acellular pertussis vaccines,” reported Dr. Nicola P. Klein and her associates at the Kaiser Permanente Vaccine Study Center in Oakland, Calif. “This study demonstrates that despite high rates of Tdap vaccination, the growing cohort of adolescents who have only received acellular pertussis vaccines continue to be at high risk of contracting pertussis and sustaining epidemics,” they wrote online (Pediatrics. 2016 Feb 5. [doi: 10.1542/peds.2015-3326]).

©CDC

The researchers tracked 279,493 members of Kaiser Permanente Northern California who had received only DTaP vaccines, as opposed to the whole-cell DTwP formulation previously used, from age 10 onward. These included all members who were born from 1999 onward or were born from 1996-1998 and received three infant doses of DTaP, excluding children who had previously received Tdap or had pertussis. Among these, 175,094 children received the Tdap.

For the purposes of tracking pertussis cases in unvaccinated versus vaccinated adolescents, individuals were considered unvaccinated in the analysis until they received their first Tdap, after which they were vaccinated and time since vaccination was a continuous variable. Overall, 96.5% of the children were vaccinated by their 14th birthday.

Across 792,418 person-years between January 2006 and March 2015, including 418,595 vaccinated person-years for the children who received the Tdap, 1,207 cases of pertussis occurred. The vast majority of these – 85% – occurred among those ages 10-13 years. Teens aged 14-16 years comprised 15% of the cases, and only 0.5% of cases occurred among older teens. During each year of outbreaks, incidence dropped off precipitously among the age groups composed of children who would have received the whole-cell pertussis vaccine.

For example, “pertussis incidence in the 2010 outbreak sharply declined after this peak [of 10- to 11-year-olds] and stayed low at older ages, a decline that we have previously demonstrated to be associated with the receipt of whole cell instead of acellular pertussis vaccines in infancy and childhood as well as with Tdap receipt,” the authors wrote.

The researchers estimated the Tdap’s effectiveness at 69% throughout the first year after vaccination. This dropped to 57% in the second year after vaccination and then to 25% in the third year. By 4 years or later after Tdap receipt, the vaccine’s effectiveness sat at just 9%.

For each year after Tdap vaccination, children’s risk of pertussis increased 35% (hazard ratio, 1.35), and cases were mild or moderate regardless of vaccination status. Nearly all (98%) of the children with pertussis had visited the doctor within 5 days on either side of their positive polymerase chain reaction test, 86% received a diagnosis of pertussis, and 96% received a prescription for azithromycin, except for 1 for erythromycin. In addition, 4% (50) of the cases visited the emergency department. No differences in rate of ED visits or prescriptions existed between vaccinated and unvaccinated children.

“The strategy of routinely vaccinating adolescents to prevent future disease did not prevent the 2014 epidemic, arguably because the protection afforded by a dose of Tdap was too short-lived,” the authors noted. They also pointed out that Tdap waning estimates likely also include ongoing DTaP waning.“This study was unable to disentangle the waning of Tdap effectiveness from the ongoing waning of previous doses of DTaP because the years since vaccination for Tdap and the fifth DTaP dose are closely correlated,” they wrote.

Most of the Tdap vaccines administered were Adacel (Sanofi Pasteur), but Boostrix (GlaxoSmithKline) was used as well. Waning occurred in both brands, and although not directly compared, no major differences in waning seemed to exist.

“We expect future pertussis epidemics to be larger as the cohort that has only received acellular pertussis vaccines ages,” the authors concluded. “The results in this study raise serious questions regarding the benefits of routinely administering a single dose of Tdap to every adolescent aged 11 or 12 years.”

The research was funded by Kaiser Permanente. Dr. Klein has received research funding from GlaxoSmithKline for a separate pertussis vaccine effectiveness study, and Dr. Klein and one coauthor also have received research funding from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, Novartis, Protein Science, Nuron Biotech, and MedImmune. The remaining coauthors said they had no relevant financial disclosures. GlaxoSmithKline and Sanofi Pasteur manufacture the pertussis vaccines purchased by Kaiser Permanente for this study.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Tdap effectiveness wanes rapidly in teens
Display Headline
Tdap effectiveness wanes rapidly in teens
Legacy Keywords
Tdap vaccine, DtaP, efficacy, wanes, rapid, teens, adolescents, whooping cough, pertussis
Legacy Keywords
Tdap vaccine, DtaP, efficacy, wanes, rapid, teens, adolescents, whooping cough, pertussis
Sections
Article Source

FROM PEDIATRICS

PURLs Copyright

Inside the Article

Vitals

Key clinical point: Tdap protection against pertussis in adolescents wanes rapidly after the first year.

Major finding: Tdap effectiveness against pertussis dropped from 68.6% effective in the first year after vaccination to 8.9% by 4 years later; each year after Tdap increased the risk of pertussis in vaccinated teens by 35% (hazard ratio per year: 1.35).

Data source: The findings are based on analysis of 1,207 cases of pertussis among 279,493 California teens who were unvaccinated or who received the Tdap booster after recommended childhood doses of DTaP.

Disclosures: The research was funded by Kaiser Permanente. Dr. Klein has received research funding from GlaxoSmithKline for a separate pertussis vaccine effectiveness study, and Dr. Klein and one coauthor also have received research funding from GlaxoSmithKline, Sanofi Pasteur, Pfizer, Merck, Novartis, Protein Science, Nuron Biotech and MedImmune. The remaining coauthors said they had no relevant financial disclosures. GlaxoSmithKline and Sanofi Pasteur manufacture the pertussis vaccines purchased by Kaiser Permanente for this study.